IIOT-OXYS, INC.(2)

 false 2023 FY 0001290658

 2023-06-30

 2024-07-02

 2023-10-01

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SalesRevenueNetMember
 us-gaap: CustomerConcentrationRiskMember
 ITOX:OneCustomerMember

 us-gaap: SalesRevenueNetMember
 us-gaap: CustomerConcentrationRiskMember
 ITOX:OneCustomerMember

 2022-04-04

 2022-04-03
 2022-04-04

 ITOX:StockIncentivePlan2017Member

 ITOX:StockIncentivePlan2017Member

 ITOX:StockIncentivePlan2019Member

 ITOX:StockIncentivePlan2019Member

 2022-03-18

 2022-06-01

 ITOX:April12023Member

 ITOX:April12024Member

 ITOX:April12025Member

 ITOX:April12023Member

 ITOX:April12024Member

 ITOX:April12025Member

 us-gaap: ConvertibleNotesPayableMember

 us-gaap: ConvertibleNotesPayableMember

 ITOX:ConvertibleNotesPayableOneMember

 ITOX:ConvertibleNotesPayableOneMember

 ITOX:ConvertibleNotesPayableTwoMember

 ITOX:ConvertibleNotesPayableTwoMember

 ITOX:ConvertibleNotesPayableThreeMember

 ITOX:ConvertibleNotesPayableThreeMember

 ITOX:ConvertibleNotesPayableFourMember

 ITOX:ConvertibleNotesPayableFourMember

 ITOX:ConvertibleNotesPayableFiveMember

 ITOX:ConvertibleNotesPayableFiveMember

 2023-07-20
 2023-07-21

 2023-07-20
 2023-07-21

 2022-04-28
 2022-04-29

 2023-03-22
 2023-03-23

 2023-04-26
 2023-04-27

 2022-04-28
 2022-04-29

 2023-09-29
 2023-10-02

 2023-10-02

 2023-11-13
 2023-11-14

 2023-11-14

 2023-12-13
 2023-12-14

 2023-12-14

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 us-gaap: ConvertibleNotesPayableMember

 us-gaap: ConvertibleNotesPayableMember

 ITOX:StockholderMember

 ITOX:StockholderMember

 ITOX:StockholderMember

 ITOX:StockholderMember

 2021-03-01

 2021-08-02

 ITOX:DirectorsAndOfficersMember

 ITOX:DirectorsAndOfficersMember

 2024-03-31

 ITOX:CommonStockPurchaseAgreementMember

 ITOX:ConsultantMember

 2023-03-23

 2023-04-27

 2023-10-16
 2023-10-17

 2023-10-17

 2023-11-13
 2023-11-14

 2023-12-13
 2023-12-14

 ITOX:NoteBAndNoteGMember

 ITOX:StockIncentivePlan2017Member

 2017-12-14

 ITOX:StockIncentivePlan2019Member

 2019-03-11

 srt: OfficerMember

 srt: DirectorMember

 ITOX:AdvisorMember

 2022-10-01
 2022-10-03

 ITOX:OfficerAdvisorAndDirectorMember

 ITOX:OfficerAdvisorAndDirectorMember

 ITOX:SeriesASupervotingConvertiblePreferredStockMember

 2020-07-02

 ITOX:SeriesASupervotingConvertiblePreferredStockMember

 ITOX:SeriesASupervotingConvertiblePreferredStockMember

 ITOX:SeriesBConvertiblePreferredStockEquityFinancingMember

 2020-11-16

 2020-11-18
 2020-11-19

 ITOX:CommitmentFeeMember

 2020-11-18
 2020-11-19

 ITOX:AdditionalSaleMember

 2020-11-18
 2020-11-19

 2020-11-19

 2020-12-15
 2020-12-16

 2020-12-16

 2021-12-19
 2021-12-20

 us-gaap: SeriesAPreferredStockMember

 2021-01-01

 2022-02-06
 2022-02-07

 2022-02-07

 2022-03-23
 2022-03-24

 2022-03-24

 2022-11-16
 2022-11-17

 2022-11-17

 ITOX:IssuedAugust2023Member

 2023-08-23
 2023-08-24

 ITOX:IssuedAugust2023Member

 2023-08-24

 ITOX:IssuedAugust2023Member

 ITOX:IssuedAugust2023Member

 2021-01-01

 Table
of Contents

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K

. ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2023

. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from __________ to __________

 Commission File Number: 000-50773

 IIOT-OXYS, INC.

 (Exact name of Registrant as specified in its charter)

 Nevada

 81-3485426

 (State or other jurisdiction of incorporation

or organization)

 (I.R.S. Employer Identification No.)

 705 Cambridge Street, Cambridge, Massachusetts

 02141

 (Address of principal executive offices)

 (Zip Code)

 Issuer's telephone number, including area
code: ( 401) 307-3092

 Securities registered pursuant to Section 12(b)
of the Act:

 Title of each class

 Trading Symbol(s)

 Name of each exchange on which registered

 N/A

 N/A

 N/A

 Securities registered pursuant to Section 12(g)
of the Act: Common Stock, Par Value $0.001

 Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

(1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. (1) Yes No (2) Yes
 No

has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
 No

is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company",
and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one)

 Large accelerated filer

 Accelerated filer

.

 Non-accelerated filer

.

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.

has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.

 If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements.

 Indicate by check mark
whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by
any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

is a shell company (as defined in Rule 12b-2 of the Act). Yes
No

 The aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant as of the last business day of its most recently completed second fiscal quarter
based upon the price at which the common equity was last sold was $ 801,867.

 As of July 2, 2024, there were 555,015,293
shares of the registrant's Common Stock outstanding.

 DOCUMENTS INCORPORATED BY REFERENCE

 None

 Item 1. Business

 Item 1A. Risk Factors

 Item 1B. Unresolved Staff Comments

 Item 1C. Cybersecurity

 Item 2. Properties

 Item 3. Legal Proceedings

 Item 4. Mine Safety Disclosures

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6. [Reserved]

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A. Quantitative And Qualitative Disclosures About Market Risk

 Item 8. Financial Statements

 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

 Item 9A. Controls and Procedures

 Item 9B. Other Information

 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 item 10. Directors, Executive Officers and Corporate Governance

 ITEM 11. Executive Compensation

 Item 12. Security Ownership of Certain Beneficial Owners and Management

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 Item 14. Principal Accountant Fees and Services

 Item 15. Exhibits, Financial Statement Schedules

 Item 16 Form 10-K Summary

 SIGNATURES

 i

 Forward-Looking Statements

 The statements contained in this report that are
not historical facts are forward-looking statements that represent management's beliefs and assumptions based on currently available
information. Forward-looking statements include the information concerning possible or assumed future operations, business strategies,
need for financing, competitive position, potential growth opportunities, ability to retain and recruit personnel, the effects of competition
and the effects of future legislation or regulations. Forward-looking statements include all statements that are not historical facts
and can be identified by the use of forward-looking terminology such as the words "believes," "intends," "may,"
"should," "anticipates," "expects," "could," "plans," or comparable terminology
or by discussions of strategy or trends. Although we believe that the expectations reflected in such forward-looking statements are reasonable,
we cannot give any assurances that these expectations will prove to be correct. Such statements by their nature involve risks and uncertainties
that could significantly affect expected results, and actual future results could differ materially from those described in such forward-looking
statements.

 Factors that may cause differences between actual
results and those contemplated by forward-looking statements are not limited to the following:

 the unprecedented impact of COVID-19 pandemic on our business, customers, employees, subcontractors, consultants, service providers, stockholders, investors and other stakeholders;

 the impact of conflict between the Russian Federation and Ukraine on our operations;

 geo-political events, such as the crisis in Ukraine, government responses to such events and the related impact on the economy both nationally and internationally;

 general market and economic conditions;

 our ability to acquire new customers;

 our ability to maintain and grow our business with our current customers;

 our ability to meet the volume and service requirements of our customers;

 industry consolidation, including acquisitions by us or our competitors;

 capacity utilization and the efficiency of manufacturing operations;

 success in developing new products;

 timing of our new product introductions;

 new product introductions by competitors;

 the ability of competitors to more fully leverage low cost geographies for manufacturing or distribution;

 product pricing, including the impact of currency exchange rates;

 effectiveness of sales and marketing resources and strategies;

 adequate manufacturing capacity and supply of components and materials;

 strategic relationships with our suppliers;

 product quality and performance;

 protection of our products and brand by effective use of intellectual property laws;

 the financial strength of our competitors;

 the outcome of any future litigation or commercial dispute;

 barriers to entry imposed by competitors with significant market power in new markets;

 government actions throughout the world; and

 our ability to service debt, when due.

 Although the forward-looking statements in this
Annual Report on Form 10-K (the " Annual Report ") are based on our beliefs, assumptions and expectations, taking into
account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes.
No assurance can be made by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations
from them will not be material and adverse. We undertake no obligation, other than as maybe be required by law, to update this Annual
Report or otherwise make public statements updating our forward-looking statements.

 Introductory Comment

 Unless otherwise indicated, any reference to "the
Company", "our company", "we", "us", or "our" refers to IIOT-OXYS, Inc., a Nevada
corporation, and as applicable to its wholly owned subsidiaries, OXYS Corporation, a Nevada corporation, and HereLab, Inc., a Delaware
corporation.

 ii

 Item 1.
 Business

 Historical Background

 We were incorporated in the State of New Jersey
on October 1, 2003 under the name of Creative Beauty Supply of New Jersey Corporation, and subsequently changed our name to Gotham Capital
Holdings, Inc. on May 18, 2015. We commenced operations in the beauty supply industry as of January 1, 2004. On November 30, 2007, our
Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. From January 1, 2009 until July 28,
2017, we had no operations and were a shell company.

 On March 16, 2017, our Board of Directors adopted
resolutions, which were approved by shareholders holding a majority of our outstanding shares, to change our name to "IIOT-OXYS,
Inc.", to authorize a change of domicile from New Jersey to Nevada, to authorize a 2017 Stock Awards Plan, and to approve the Securities
Exchange Agreement (the " OXYS SEA ") between the Company and OXYS Corporation (" OXYS "), a Nevada
corporation incorporated on August 4, 2016.

 Under the terms of the OXYS SEA we acquired 100%
of the issued voting shares of OXYS in exchange for 34,687,244 shares of our Common Stock. We also cancelled 1,500,000 outstanding shares
of our Common Stock and changed our management to Mr. DiBiase who also served in the management of OXYS. Also, one of our principal shareholders
entered into a consulting agreement with OXYS to provide consulting services during the transition. The OXYS SEA was effective on July
28, 2017, and our name was changed to "IIOT-OXYS, Inc." at that time. Effective October 26, 2017, our domicile was changed
from New Jersey to Nevada.

 At the present time, we have two wholly owned
subsidiaries which are OXYS Corporation and HereLab, Inc. (an entity immaterial to our operations), through which our operations are conducted.

 General Overview

 IIOT-OXYS, Inc., a Nevada corporation (the " Company "),
and OXYS, were originally established for the purposes of designing, building, testing, and selling Edge Computing systems for the Industrial
Internet. Both companies were, and presently are, early stage technology startups that are largely pre-revenue in their development
phase. The Company received its first revenues in the last quarter of 2017, has continued to realize revenues in 2023, and expects
moderate revenue growth in 2024 due to limited ability to raise funds for sales and marketing efforts.

 We develop hardware, software and algorithms that
monitor, measure and predict conditions for energy, structural, agricultural and medical applications. We use domain-specific Artificial
Intelligence to solve industrial and environmental challenges. Our engineered solutions focus on common sense approaches to machine learning,
algorithm development and hardware and software products. We design a system of hardware and software, assemble, install, monitor data
and apply our algorithms to help provide the customer insights.

 We use off-the-shelf components, with reconfigurable
hardware architecture that adapts to a wide range of customer needs and applications. We use open-source software tools, while still creating
proprietary content for customers, thereby reducing software development time and cost. The software works with the hardware to collect
data from the equipment or structure that is being monitored.

 We focus on developing insights. We develop algorithms
that help our customers create insights from vast data streams. The data collected is analyzed and reports are created for the customer.
From these insights, the customer can act to improve their process, product or structure.

 OUR SOLUTIONS ACHIEVE TWO OBJECTIVES

 ADD VALUE

 We show clear path to improved asset reliability, machine uptime, machine utilization, energy consumption, and quality.

 We provide advanced algorithms and insights as a service.

 RISK MINIMIZATION

 We use simple measurements which are minimally invasive.

 We do not interfere with command and control of critical equipment.

 We do not interfere with machine control networks.

 HOW WE DO IT

 Our location in Cambridge, Massachusetts is ideal
since market-leading Biotech, Medtech, and Pharma multinational firms have offices, manufacturing plants and/ or R&D centers in Cambridge
or the Greater Boston area, which gives us easier access to potential sales which, in turn, lowers our cost of sales. Additionally, we
continue to gain traction in the structural health monitoring and smart manufacturing industries. We, therefore, have a range of opportunities
as we continue to expand our customer base.

 Our goals are to augment visual bridge inspection
with instrumentation and predictive algorithms for structural health monitoring and help Biotech, Pharma, and Medical Device companies
realize the next wave of performance, productivity, and quality gains for their organizations, through our Smart Manufacturing/Industry
4.0 technology and Artificial Intelligence (AI) and Machine Learning algorithms.

 We have a unique value proposition in a fast-growing
worldwide multi-billion USD market and have positioned our business with strategic partners for accelerated growth. Given adequate funding
for sales and marketing efforts, we believe that potential growth for 2024 and beyond is possible.

 WHAT MARKETS WE SERVE

 SMART MANUFACTURING – MEDICAL DEVICES,
BIOTECH, AND PHARMACEUTICAL SUPPLY CHAIN

 We help our customers maintain machine uptime
and maximize operational efficiency. We also enable then to do energy monitoring, predictive maintenance that anticipates problems before
they happen, and improve part and process quality. We are on the operations side, not the patient-facing side. In this market vertical,
our customers must provide high-quality products that must also pass rigorous review by governing bodies such as the FDA. Here again,
we focus on machine uptime, operational efficiency, and predictive maintenance to avoid unplanned downtime.

 SMART INFRASTRUCTURE

 For bridges and other civil infrastructure, local,
state and federal agencies have limited resources. We help our clients prioritize how to spend limited funds by addressing those fixes
which need to be made first.

 OUR UNIQUE VALUE PROPOSITION

 EDGE COMPUTING AS A COMPLIMENT TO CLOUD COMPUTING

 Within the Internet of Things (" IoT ")
and Industrial Internet of Things (" IIoT "), most companies right now are adopting an approach which sends all sensor
data to the cloud for processing. We specialize in edge computing, where the data processing is done locally right where the data is collected.
We also have advanced cloud-based algorithms that implement various machine learning and artificial intelligence algorithms.

 ADVANCED ALGORITHMS

 We have sought to differentiate from our competitors
by developing advanced algorithms on our own and in collaboration with strategic partners These algorithms are an essential part of the
edge computing strategy that convert raw data into actionable knowledge right where the data is collected without having to send the data
to the cloud first.

 RECONFIGURABLE HARDWARE AND SOFTWARE

 Instead of focusing on creating tools, we use
open-source tools to create proprietary content.

 Marketing

 Our marketing and sales efforts are divided into
several distinct categories:

 1)

 We work with partners to leverage their sales and marketing channels.

 2)

 Direct business development and discussions with end use customers by company management; and

 3)

 Trade shows and international technical, sales and marketing meetings.

 Competition

 We have two principal sources of competition.
The first comes from large companies such as Siemens, PTC, IBM, GE, Amazon, Google, etc., who all have their efforts in IIoT. However,
these large companies are cloud – computing centric and they are trying to move towards edge devices from their present position
of being solely cloud computing based. We will be starting in edge computing from day one as opposed to force-fitting a cloud-based solution
into the limited computational capability and storage space of an edge device. We believe our systems will be more computationally efficient
as compared to a cloud-based solution which requires more computational resources.

 The second source of competition is from startups
who are in the edge computing space. Examples are FogHorn Systems Inc., Tulip Interfaces, and MachineSense. There will be additional startups
that will specifically target the edge computing space as the investor awareness and the technical focus shifts from cloud computing to
edge computing. Whereas other startups focus on development of proprietary tools for edge computing, our solutions will use open-source
tools but will still create proprietary algorithms and software content for clients and customers. We feel this methodology of creating
proprietary solutions using open-source tools will allow us to rapidly address current and future customer needs.

 Government Regulation

 At present, we do not require any governmental
approval of any of our products or services.

 Environmental Laws

 At present, we are not regulated by any environmental
laws.

 Research and Development

 We work with our partners and universities to
develop IP.

 Other than expenses for legal, accounting, audit,
tax preparation, intellectual property (IP), and other overhead expenses such rent, most of our funds are spent on technology development,
product development, and research and development.

 The efforts in research and development have already
resulted in significant customer interest in various market verticals including industrial, automotive, aerospace, agricultural, infrastructure,
and power generation.

 Intellectual Property

 On February 5, 2018, we entered into a Non-Exclusive
Patent License Agreement with MIT. The agreement, which was effective February 1, 2018, granted to us a royalty-bearing non-exclusive
license under U.S. Patent Nos. 8344724 ("Non-Intrusive Monitoring of Power and Other Parameters" issued January 1, 2013),
14/263407 ("Non-Intrusive Monitoring" filed April 28, 2014), and Patent Cooperation Treaty Serial No. PCT/US2016/057165 ("Noncontact
Power Sensing" filed October 14, 2016) during the term of the agreement. The term of the agreement was from the effective date until
the expiration or abandonment of all issued patents and filed patent applications licensed pursuant to the agreement, unless terminated
earlier in accordance with the agreement.

 Under the agreement, we were required to make
a first commercial sale of a "LICENSED PRODUCT" and/or a first commercial performance of a "LICENSED PROCESS,"
as defined in the agreement, on or before September 30, 2018. We had negotiated revenue targets with MIT which would determine annual
royalty payments. The 2018 minimum revenue target for the sale of products and services incorporating the MIT technology was $100,000.
This minimum revenue amount would increase in subsequent years.

 Within 30 days of invoicing, a non-refundable
license issue fee of $10,000 was paid by us to MIT. Pursuant to the agreement, we were required to pay MIT additional patent maintenance
fees in years beyond 2018.

 Pursuant to the agreement, we were required to
pay to MIT a running royalty of 2% of "NET SALES," as defined in the agreement made in the calendar years 2018, 2019, and
2020. For "NET SALES" made in the calendar year 2021 and every calendar year thereafter through the term of the agreement,
we were required to pay MIT a running royalty of 4%.

 On October 31, 2018, we sent written notice of
our intent to terminate the agreement with an effective date of termination of April 30, 2019. Since none of the technology licensed to
us by MIT had been used by us in any of our products and we had been investing in the development of our own intellectual property,
we determined the technology that was licensed from MIT wasn't necessary in the near term. Due to this, the written notice
sent by us expressed a desire by our management to renegotiate the terms of the agreement with MIT.

 MIT declined to renegotiate the terms of the agreement,
and, on December 6, 2018, we received a notice of termination from MIT due to non-payment of fees. As of December 6, 2018, the agreement
was terminated, fees are no longer accruing, interest is accruing and $76,284 in fees owed to MIT are still owing as of the date of this
Annual Report. Despite the termination of the Agreement, we remain active with MIT as a member of the MIT Startup Exchange (STEX). The
purpose of STEX is to promote collaboration and partnerships between MIT-connected startups and members of MIT's Industrial Liaison
Program. We remain open to future mutually acceptable agreements with MIT.

 Our common stock is quoted on the OTC Pink under
the symbol "ITOX." The table below sets forth for the periods indicated the quarterly high and low bid prices as reported
by OTC Markets. Limited trading volume has occurred during these periods. These quotations reflect inter-dealer prices, without retail
mark-up, mark-down, or commission and may not necessarily represent actual transactions.

 Customers

 Due to our status of a start-up, at the moment,
we depend on a few major customers. This should change as we implement plans for future growth.

 Employees

 As of June 26, 2024, we have two
full-time employees, including the CEO (and Interim CTO) and COO (and Interim CFO).

 At the present time, except for the funding received
from Cambridge MedSpace LLC and Vidhyadhar Mitta in the form of secured notes, there are no conflicts of interest between the Company
and any of our officers and directors. This was determined as follows: i) none of their outside activities are soliciting business from
our customers or business contacts; ii) they are not soliciting our investors to invest in other ventures; and iii) they are not soliciting
our contract employees to leave us and join other efforts. At present, all our business services are provided by outside contractors.

 Legal Proceedings

 We are currently not aware of any such legal proceedings
or claims that we believe will have, individually or in aggregate, a material adverse effect on our business, financial condition or operating
results. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time
that may harm our business.

 Item 1A.
 Risk Factors

 As a Smaller Reporting Company, we are not required
to furnish information under this Item 1A.

 Item 1B.
 Unresolved Staff Comments

 Not applicable.

 Item 1C.
 Cybersecurity

 For purposes of this section:

 "Cybersecurity incident" means
an unauthorized occurrence, or a series of related unauthorized occurrences, on or conducted through our information systems that jeopardizes
the confidentiality, integrity, or availability of our information systems or any information residing therein.

 "Cybersecurity threat" means
any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality,
integrity, or availability of our information systems or any information residing therein.

 "Information systems" means
electronic information resources, owned or used by us, including physical or virtual infrastructure controlled by such information resources,
or components thereof, organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of our information
to maintain or support our operations.

 Risk Management and Strategy

 Our website is monitored by a third party to check
if our website is secure. We are prepared to inform all parties necessary if any breach of cyber-security were to happen. We have never
had this problem and so we have never had to inform consultants, auditors, or other third parties.

 We have never had a breach of cyber-security at
any point in our past. The risk to us of cybersecurity threats is in data storage of customer questions and emails. A breach of customers'
data could negatively materially affect our public trust and could result in loss of customers and revenue.

 Governance

 Our board of directors has no specific processes
for monitoring cybersecurity within the company. There is no subcommittee specifically for monitoring cybersecurity in the company.

 Our management monitors our websites and online
accounts frequently to manage risks associated with cyber-security risks. Our management communicates with our board on matters of cybersecurity
but, has not had to inform them of any breaches thus far.

 Item 2.
 Properties

 We currently do not own any properties. We entered
into a yearly lease agreement for our principal office located in Cambridge, Massachusetts on August 1, 2017 which began on January 1,
2018 and terminated on December 31, 2018. We entered into a new lease agreement on March 12, 2019, which began on January 1, 2019, and
terminated on June 30, 2019. Pursuant to the lease, we are obligated to pay the landlord monthly installments of $2,000 for a total lease
payment of $12,000 in 2019. We secured a 2 nd lease for July – December 2019 at $2,000/month for an additional $12,000
in 2019. As of 2023, we reduced the amount of space required and have renegotiated the lease terms to $250/month. This is a month-to-month
agreement.

 Item 3.
 Legal Proceedings

 We are currently not aware of any such legal proceedings
or claims that we believe will have, individually or in aggregate, a material adverse effect on our business, financial condition or operating
results. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time
that may harm our business.

 Item 4.
 Mine Safety Disclosures

 Not Applicable.

 Item 5.
 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities

 Market Information

 Our common stock is quoted on the OTC Pink under
the symbol "ITOX." The table below sets forth for the periods indicated the quarterly high and low bid prices as reported
by OTC Markets. Limited trading volume has occurred during these periods. These quotations reflect inter-dealer prices, without retail
mark-up, mark-down, or commission and may not necessarily represent actual transactions.

 Quarter

 High

 Low

 FISCAL YEAR ENDING DECEMBER 31, 2024

 First

 $

 0.0012

 $

 0.0005

 Quarter

 High

 Low

 FISCAL YEAR ENDED DECEMBER 31, 2023

 First

 $

 0.0087

 $

 0.0013

 Second

 $

 0.0029

 $

 0.0011

 Third

 $

 0.0024

 $

 0.0009

 Fourth

 $

 0.0012

 $

 0.0006

 Quarter

 High

 Low

 FISCAL YEAR ENDED DECEMBER 31, 2022

 First

 $

 0.0195

 $

 0.0049

 Second

 $

 0.0219

 $

 0.005

 Third

 $

 0.0071

 $

 0.0031

 Fourth

 $

 0.0048

 $

 0.0018

 Our common stock is considered to be penny stock
under rules promulgated by the SEC. Under these rules, broker-dealers participating in transactions in these securities must first deliver
a risk disclosure document which describes risks associated with these stocks, broker-dealers' duties, customers' rights and
remedies, market and other information, and make suitability determinations approving the customers for these stock transactions based
on financial situation, investment experience and objectives. Broker-dealers must also disclose these restrictions in writing, provide
monthly account statements to customers, and obtain specific written consent of each customer. With these restrictions, the likely effect
of designation as a penny stock is to decrease the willingness of broker-dealers to make a market for the stock, to decrease the liquidity
of the stock and increase the transaction cost of sales and purchases of these stocks compared to other securities.

 Holders

 As of the close of business on June 26,
2024, we had approximately 155 holders of our common stock. The number of record holders was determined from the records of our
transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security
brokers, dealers, and registered clearing agencies. We have appointed Issuer Direct, 1981 East 4800 South, Suite 100, Salt Lake
City, UT 84117, to act as transfer agent for the common stock.

 Dividends

 We have never declared a cash dividend on our
common stock and our Board of Directors does not anticipate that we will pay cash dividends in the foreseeable future. Any future determination
to pay cash dividends will be at the discretion of our board of directors and will depend upon our financial condition, operating results,
capital requirements, restrictions contained in our agreements and other factors which our Board of Directors deems relevant.

 We are obligated to pay dividends to certain holders
of our preferred stock which we pay out of legally available funds from time to time or reach arrangements with our holders of preferred
stock to convert limited quantities of preferred stock at favorable conversion prices in lieu of dividend payments.

 Securities Authorized for Issuance under Equity Compensation
Plans

 Equity
Compensation Plan Information

 Plan category

 Number of
 securities to be
 issued upon
 exercise of
 outstanding
 options, warrants
 and rights

 Weighted-average
 exercise price of
 outstanding
 options, warrants
 and rights

 Number of
 securities
 remaining
 available for
 future issuance
 under equity
 compensation
 plans (excluding
 securities
 reflected in
 column (a))

 (a)

 (b)

 (c)

 Equity compensation plans approved by security holders

 $
 –

 $
 –

 –

 Equity compensation plans not approved by security holders

 16,490,609

 $
 0.0448

 8,322,212
 (1)

 Total

 $
 16,490,609

 8,322,212

 (1)

 Of the 24,522,212 shares remaining for future issuance under equity compensation plans, 15,100,000 shares of Common Stock have been awarded but are unvested.

 2017 Stock Incentive Plan

 On March 16, 2017, our board of directors assumed
the 2017 Stock Awards Plan adopted by the Company while domiciled in New Jersey. No awards were made under this plan. On December 14,
2017, the Board of Directors terminated this plan and adopted a new 2017 Stock Incentive Plan (the " 2017 Plan "). The
purposes of the 2017 Plan are (a) to enhance our ability to attract and retain the services of qualified employees, officers, directors,
consultants, and other service providers upon whose judgment, initiative and efforts the successful conduct and development of our business
largely depends, and (b) to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement
and betterment of our company, by providing them an opportunity to participate in the ownership of our Company and thereby have an interest
in the success and increased value of our Company.

 There are 4,500,000 shares of common stock authorized
for non-qualified and incentive stock options, restricted stock units, restricted stock grants, and stock appreciation rights under the
2017 Plan, which are subject to adjustment in the event of stock splits, stock dividends, and other situations.

 The 2017 Plan is administered by our board of
directors; however, the board of directors may designate administration of the 2017 Plan to a committee consisting of at least two independent
directors. Only employees of our Company or of an "Affiliated Company", as defined in the 2017 Plan, (including members of
the board of directors if they are employees of our Company or of an Affiliated Company) are eligible to receive incentive stock options
under the Plan. Employees of our Company or of an Affiliated Company, members of the board of directors (whether or not employed by our
company or an Affiliated Company), and "Service Providers", as defined in the 2017 Plan, are eligible to receive non-qualified
options, restricted stock units, and stock appreciation rights under the 2017 Plan. All awards are subject to Section 162(m) of the Internal
Revenue Code.

 No option awards may be exercisable more than
ten years after the date it is granted. In the event of termination of employment for cause, the options terminate on the date of employment
is terminated. In the event of termination of employment for disability or death, the optionee or administrator of optionee's estate
or transferee has six months following the date of termination to exercise options received at the time of disability or death. In the
event of termination for any other reason other than for cause, disability or death, the optionee has 30 days to exercise his or her options.

 The 2017 Plan will continue in effect until all
the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until ten years after
its adoption, whichever is earlier. Awards under the 2017 Plan may also be accelerated in the event of certain corporate transactions
such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all our assets.

 As of December 31, 2023, there were 3,547,788
shares of Common Stock issued with 952,212 remaining for awards under the 2017 Plan.

 2019 Stock Incentive Plan

 On March 11, 2019, the Board of Directors adopted
the 2019 Stock Incentive Plan (the " 2019 Plan "). The purposes of the 2019 Plan are (a) to enhance our ability to attract
and retain the services of qualified employees, officers, directors, consultants, and other service providers upon whose judgment, initiative
and efforts the successful conduct and development of our business largely depends, and (b) to provide additional incentives to such persons
or entities to devote their utmost effort and skill to the advancement and betterment of our company, by providing them an opportunity
to participate in the ownership of our Company and thereby have an interest in the success and increased value of our Company.

 The 2019 Plan is administered by our board of
directors; however, the board of directors may designate administration of the 2019 Plan to a committee consisting of at least two independent
directors. Awards may be made under the Plan for up to 5,000,000 shares of common stock of the Company. Only employees of our Company
or of an "Affiliated Company", as defined in the 2019 Plan, (including members of the board of directors if they are employees
of our Company or of an Affiliated Company) are eligible to receive incentive stock options under the 2019 Plan. Employees of our Company
or of an Affiliated Company, members of the board of directors (whether or not employed by our company or an Affiliated Company), and
"Service Providers", as defined in the 2019 Plan, are eligible to receive non-qualified options, restricted stock units, and
stock appreciation rights under the 2019 Plan. All awards are subject to Section 162(m) of the Internal Revenue Code.

 No option awards may be exercisable more than
ten years after the date it is granted. In the event of termination of employment for cause, the options terminate on the date of employment
is terminated. In the event of termination of employment for disability or death, the optionee or administrator of optionee's estate
or transferee has six months following the date of termination to exercise options received at the time of disability or death. In the
event of termination for any other reason other than for cause, disability or death, the optionee has 30 days to exercise his or her options.

 The 2019 Plan will continue in effect until all
the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until ten years after
its adoption, whichever is earlier. Awards under the 2019 Plan may also be accelerated in the event of certain corporate transactions
such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all our assets.

 As of December 31, 2023, there were 3,330,000
shares of shares Common Stock awarded with 1,670,000 shares remaining for awards under the 2019 Plan.

 2022 Stock Incentive Plan

 On March 18, 2022, the Board of Directors adopted
the 2022 Stock Incentive Plan (the " 2022 Plan "). The purposes of the 2022 Plan are (a) to enhance our ability to attract
and retain the services of qualified employees, officers, directors, consultants, and other service providers upon whose judgment, initiative
and efforts the successful conduct and development of our business largely depends, and (b) to provide additional incentives to such persons
or entities to devote their utmost effort and skill to the advancement and betterment of our company, by providing them an opportunity
to participate in the ownership of our Company and thereby have an interest in the success and increased value of our Company.

 The 2022 Plan is administered by our board of
directors; however, the board of directors may designate administration of the 2022 Plan to a committee consisting of at least two independent
directors. Awards may be made under the Plan for up to 20,000,000 shares of common stock of the Company. Only employees of our Company
or of an "Affiliated Company", as defined in the 2022 Plan, (including members of the board of directors if they are employees
of our Company or of an Affiliated Company) are eligible to receive incentive stock options under the 2022 Plan. Employees of our Company
or of an Affiliated Company, members of the board of directors (whether or not employed by our company or an Affiliated Company), and
"Service Providers", as defined in the 2022 Plan, are eligible to receive non-qualified options, restricted stock units, and
stock appreciation rights under the 2022 Plan. All awards are subject to Section 162(m) of the Internal Revenue Code.

 No option awards may be exercisable more than
ten years after the date it is granted. In the event of termination of employment for cause, the options terminate on the date of employment
is terminated. In the event of termination of employment for disability or death, the optionee or administrator of optionee's estate
or transferee has six months following the date of termination to exercise options received at the time of disability or death. In the
event of termination for any other reason other than for cause, disability or death, the optionee has 30 days to exercise his or her options.

 The 2022 Plan will continue in effect until all
the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until ten years after
its adoption, whichever is earlier. Awards under the 2022 Plan may also be accelerated in the event of certain corporate transactions
such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all our assets.

 As of December 31, 2023, there were 14,300,000
shares of Common Stock awarded (including 11,200,000 shares awarded but unvested) with 5,700,000 shares remaining for awards under the
2022 Plan.

 Stock Options

 We currently have no outstanding stock options.

 Recent Sales of Unregistered Securities

 Equity Financing Agreement

 On November 1, 2021,
we entered into an Equity Financing Agreement with GHS Investments, LLC (" GHS ") for an equity line. Although we are
not required to sell shares under the Equity Financing Agreement, the Equity Financing Agreement gives us the option to sell to GHS up
to $2,500,000 worth of our common stock, in increments, beginning on the first trading day after the effective date of this Registration
Statement and ending on the earlier of (i) the date GHS has purchased an aggregate of $2,500,000 of our common stock pursuant to the Equity
Financing Agreement, (ii) November 1, 2023, twenty-four months from the date of execution of the Equity Financing Agreement, or (iii)
upon mutual termination of the Equity Financing Agreement (the " Open Period ").

 During the Open Period,
we may, in our sole discretion, deliver a put notice (" Put Notice ") to GHS which shall state the dollar amount requested
by us (the " Put Amount ") and number of shares intended to sell to GHS on a designated closing date. The purchase price
(the " Purchase Price ") of the common stock sold pursuant to a Put Notice will be set at 90% of the lowest volume-weighted
average price of our common stock during the ten consecutive trading day period immediately preceding the date on which we deliver the
Put Notice to GHS. We are obligated to deliver a number of shares to GHS equal to Put Amount divided by the Purchase Price in consideration
of the payment of the Put Amount.

 Below is a table of all
puts made by the Company under the Equity Financing Agreement during the year ended December 31, 2023:

 Date of Put

 Number of Shares Sold

 Total Proceeds, Net of Discounts

 Effective Price per Share

 Net Proceeds

 1/17/23

 10,650,921

 $16,557

 $0.0015545

 $16,226

 2/6/23

 16,854,990

 $27,580

 $0.0016364

 $27,029

 2/22/23

 4,097,453

 $10,057

 $0.0024545

 $9,856

 The shares issued in
reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation
D under the Securities Act, based in part on the representations of the investor. There were $1,084 in sales commissions paid to J.H.
Darbie & Co., Inc. (" J.H. Darbie ") pursuant to these transactions.

 Preferred Equity Financing
with GHS Investments, LLC

 On August 24, 2023, pursuant
to the terms of a Securities Purchase Agreement dated August 24, 2023 (the " SPA "), IIOT-OXYS, Inc., a Nevada corporation
(the " Company "), entered into a new preferred equity financing agreement with GHS Investments, LLC (" GHS ")
in the amount of $62,000. The SPA provides for GHS's purchase of 62 shares of Series B Convertible Preferred Stock (the " Preferred
Stock "), stated value $1,200 per share, for the purchase price of $62,000, or $1,000 per share.

 Under the SPA, the Company
has issued 62 shares of Preferred Stock to GHS. This sale was exempt under Rule 506(b) under Regulation D. GHS is an "accredited
investor" as defined in Rule 501 under the Securities Act. The Company did not engage in any general solicitation or advertising
in connection with the issuance of the Preferred Stock. Selling commissions in the amount of
$1,240 were paid to J.H. Darbie & Co.

 Item 6.
 [Reserved]

 Item 7.
 Management's Discussion and Analysis of Financial Condition and Results of Operations

 This Management's Discussion and Analysis
of Financial Condition and Results of Operations contain certain forward-looking statements. Historical results may not indicate future
performance. Our forward-looking statements reflect our current views about future events; are based on assumptions and are subject to
known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements.
We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any
facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee
future results, events, levels of activity, performance, or achievements.

 Basis of Presentation

 The financial information presented below
and the following Management Discussion and Analysis of the Consolidated Financial Condition, Results of Operations,
Stockholders' Equity and Cash Flow for the periods ended December 31, 2023 and 2022 gives effect to our acquisition of OXYS
Corporation (" OXYS ") on July 28, 2017 and HereLab, Inc. In accordance with the accounting reporting requirements
for the recapitalization related to the "reverse merger" of OXYS, the consolidated financial statements for OXYS have
been adjusted to reflect the change in the shares outstanding and the par value of the common stock of OXYS. Additionally, all
intercompany transactions between the Company and its subsidiaries have been eliminated.

 Forward-Looking Statements

 Statements in this management's discussion
and analysis of financial condition and results of operations contain certain forward-looking statements. To the extent that such statements
are not recitations of historical fact, such statements constitute forward-looking statements which, by definition involve risks and uncertainties.
Where in any forward-looking statements, if we express an expectation or belief as to future results or events, such expectation or belief
is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation or
belief will result or be achieved or accomplished.

 Factors that may cause differences between actual
results and those contemplated by forward-looking statements are not limited to the following:

 the unprecedented impact of COVID-19 pandemic on our business, customers, employees, subcontractors and supply chain, consultants, service providers, stockholders, investors and other stakeholders;

 the impact of conflict between the Russian Federation and Ukraine on our operations;

 geo-political events, such as the crisis in Ukraine, government responses to such events and the related impact on the economy both nationally and internationally;

 general market and economic conditions;

 our ability to maintain and grow our business with our current customers;

 our ability to meet the volume and service requirements of our customers;

 industry consolidation, including acquisitions by us or our competitors;

 capacity utilization and the efficiency of manufacturing operations;

 success in developing new products;

 timing of our new product introductions;

 new product introductions by competitors;

 the ability of competitors to more fully leverage low-cost geographies for manufacturing or distribution;

 product pricing, including the impact of currency exchange rates;

 effectiveness of sales and marketing resources and strategies;

 adequate manufacturing capacity and supply of components and materials;

 strategic relationships with our suppliers;

 product quality and performance;

 protection of our products and brand by effective use of intellectual property laws;

 the financial strength of our competitors;

 the outcome of any future litigation or commercial dispute;

 barriers to entry imposed by competitors with significant market power in new markets;

 government actions throughout the world; and

 our ability to service secured debt, when due.

 You should not rely on forward-looking statements
in this document. This management discussion contains forward looking statements that involve risks and uncertainties. We use words such
as "anticipates," "believes," "plans," "expects," "future," "intends,"
and similar expressions to identify these forward-looking statements. Prospective investors should not place undue reliance on these statements,
which apply only as of the date of this document. Our actual results could differ materially from those anticipated in these forward-looking
statements.

 Critical Accounting Policies

 The following discussions are based upon our financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States. These financial
statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States.

 The preparation of these financial statements
requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosures of contingencies. We continually evaluate the accounting policies and estimates used to prepare financial
statements. We base our estimates on historical experiences and assumptions believed to be reasonable under current facts and circumstances.
Actual amounts and results could differ from these estimates made by management.

 Historical Background

 We were incorporated in the State of New Jersey
on October 1, 2003 under the name of Creative Beauty Supply of New Jersey Corporation and subsequently changed our name to Gotham Capital
Holdings, Inc. on May 18, 2015. We commenced operations in the beauty supply industry as of January 1, 2004. On November 30, 2007, our
Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. From January 1, 2009 until July 28,
2017, we had no operations and were a shell company.

 On March 16, 2017, our Board of Directors adopted
resolutions, which were approved by shareholders holding a majority of our outstanding shares, to change our name to "IIOT-OXYS,
Inc.", to authorize a change of domicile from New Jersey to Nevada, to authorize a 2017 Stock Awards Plan, and to approve the Securities
Exchange Agreement (the " OXYS SEA ") between the Company and OXYS Corporation (" OXYS "), a Nevada
corporation incorporated on August 4, 2016.

 Under the terms of the OXYS SEA we acquired 100%
of the issued voting shares of OXYS in exchange for 34,687,244 shares of our Common Stock. We also cancelled 1,500,000 outstanding shares
of our Common Stock and changed our management to Mr. DiBiase who also served in the management of OXYS. Also, one of our principal shareholders
entered into a consulting agreement with OXYS to provide consulting services during the transition. The OXYS SEA was effective on July
28, 2017, and our name was changed to "IIOT-OXYS, Inc." at that time. Effective October 26, 2017, our domicile was changed
from New Jersey to Nevada.

 At the present time, we have two wholly owned
subsidiaries which are OXYS Corporation and HereLab, Inc. (an entity immaterial to our operations), through which our operations are conducted.

 General Overview

 IIOT-OXYS, Inc., a Nevada corporation (the " Company "),
and OXYS, were originally established for the purposes of designing, building, testing, and selling Edge Computing systems for the Industrial
Internet. Both companies were, and presently are, early-stage technology startups that are largely pre-revenue in their development
phase. HereLab is also an early-stage technology development company. We received our first revenues in the last quarter
of 2017, continued to realize revenues until 2020 when the pandemic hit, and we realized nominal revenues through 2021 to the present.

 We develop hardware, software and algorithms that
monitor, measure and predict conditions for energy, structural, agricultural and medical applications. We use domain-specific Artificial
Intelligence to solve industrial and environmental challenges. Our engineered solutions focus on common sense approaches to machine learning,
algorithm development and hardware and software products.

 We use off the shelf components, with reconfigurable
hardware architecture that adapts to a wide range of customer needs and applications. We use open-source software tools, while still creating
proprietary content for customers, thereby reducing software development time and cost. The software works with the hardware to collect
data from the equipment or structure that is being monitored.

 We focus on developing insights. We develop algorithms
that help our customers create insights from vast data streams. The data collected is analyzed and reports are created for the customer.
From these insights, the customer can act to improve their process, product or structure.

 Results of Operations for the Year Ended
December 31, 2023 compared to the year ended December 31, 2022

 For
the year ended December 31, 2023, we earned revenues of $114,666 and incurred related cost of sales of $76,645. Our operating expenses
were $731,430 which included professional fees of $172,704, payroll costs of $244,083, amortization of intangible assets of $49,500, bad
debts of $215,069 and other general and administrative expenses of $51,029. We recorded net other expenses of $374,530 consisting of a
loss of $185,973 due to debt extinguishment on notes payable
due to change in conversion price, interest income on note receivable of $25,969, offset by interest expense of $210,426 and loss on change
in fair market value of derivative liability of $4,100. We also recorded $68,531 as preferred stock dividend on convertible preferred
stock for the year ended December 31, 2023. As a result, we incurred a net loss of $1,136,460 for
the year ended December 31, 2023.

 For the year ended December 31, 2022, we earned
revenues of $88,904 and incurred related cost of sales of $10,499. Our operating expenses were $733,071 which included professional fees
of $268,837, payroll costs of $373,774, amortization of intangible assets of $49,500, and general and administrative expenses of $40,960.
We recorded net other expenses of $369,560 consisting of recording loss on derivatives of $200,519, interest expense of $377,138 offset
by gain on change in fair market value of derivative liability of $190,462 and interest income on note receivable of $17,634. We also
recorded $52,654 as preferred stock dividend on convertible preferred stock for the year ended December 31, 2022. As a result, we incurred
a net loss of $1,076,881 for the year ended December 31, 2022.

 During the current and prior year, we did not
record an income tax benefit due to the uncertainty associated with the Company's ability to utilize the deferred tax assets.

 Revenues earned in 2023 were a substantial improvement
over the same period in 2022 (an increase of 29%). We expect revenue to moderate in 2024, as our ability to raise funding to fuel sales
& marketing efforts has been limited. Potential future revenue growth is possible, pending adequate funding for sales and marketing
efforts and building on the strength of the following factors:

 Our current DOT Bridge Monitoring Contract and overall Structural Health Monitoring (" SHM ") vertical is the foundation of our revenue stream. Discussions with our main contractor to the DOT for extensions and expansions continue to be favorable. We also continue to believe that prospects with our current DOT state, and DOT contacts in two other northeast states bode well for future business in mid-2024. There is still potential for local municipalities in our current northeast state to contribute revenue in 2024.

 Our Smart Manufacturing vertical is benefiting from the progress on our CNC SaaS contract that commenced in June 2023 and continued through the fourth quarter of 2023. In February 2024, we renewed our CNC SaaS contract with our current customer. Initial public endorsements and promotional videos have been released and additional videos are planned for release in the third quarter of 2024. These endorsements and promotional videos along with grass-roots sales & marketing efforts have generated additional sales leads for potential paid CNC POCs and additional SaaS contracts, which may contribute to revenue in the third quarter of 2024 and beyond. It is also expected these endorsements will also strengthen our position to secure additional POCs for other discrete manufacturing processes, including metal stamping, plastic injection molding, plastic extrusion, and automated assembly and test.

 Our strategic partnership development continues to be a "force multiplier" for us. The strength of our Aingura IIoT, S.L. partnership provides supplemental expertise, equipment and software, which ensures we continue to bring value to our customers. We will also continue to develop our other previously announced partnerships.

 Despite these strengths, we continue to face significant
headwinds and we have not been able to raise material funds for ongoing operations through our existing financing agreements due to market
conditions. Our CEO and COO have not received any compensation since mid-April (their salaries have accrued), and the lack of funds has
severely limited sales and marketing efforts. Our management is working to secure funding from our lead investor to pay for ongoing expenses
and the leadership team is considering its options for both the short and long term. Given the current challenges in raising adequate
funds, management is pursuing options including vetting suitable companies to merge with or acquire us.

 We believe we've created substantial value
from our business development in these industries, which have potential for success, due to the strength of their size and growth. The
global smart manufacturing (also known as Industry 4.0) was $108.9 billion in 2023 and will reach $241 billion by 2028 (CAGR 17.2%), 1
and the worldwide SHM industry is $2.5 billion in 2024 and will reach $4.1 billion by 2029 (CAGR of 10.4%). 2

 Given the valuable real-world data we have collected,
our Artificial Intelligence ("AI") Machine Learning algorithms we have developed, compelling use cases and marketing collateral
developed from our data and algorithms, combined with our experienced leadership, savvy technological talent, and prudent operational
execution, we believe our company's assets have potential continued annual revenue growth, that will be attractive to prospective
partners interested in an acquisition or merger.

 Liquidity and Capital Resources for the
Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022

 As of December 31, 2023, we reported a cash
balance of $644 as a result of decrease of $32,692 from the $33,336 cash balance at December 31, 2022. This decrease was primarily
as a result of net cash used in operating activities of $146,564 and net cash provided by financing activities of $113,872.

 Operating Activities

 Net cash flows used in operating activities for
the year ended December 31, 2023 was $146,564, primarily attributed to the net loss of $1,136,460, stock compensation expense of $4,665,
bad debts of $214,103, amortization of debt discount on notes payable and preferred stock of $12,400, amortization of intangible assets
of $49,500 and loss on extinguishment of notes payable of $186,294. The Company recorded changes in operating assets and liabilities of
$522,935 primarily attributable to decrease in accounts receivable of $4,662 due to collections from customers, decrease in prepaid expenses
and other current assets of $5,467, increase in accounts payable of $86,145 due to negotiating longer payment terms, increase in accrued
liabilities of $248,368 due to non-payment of additional interest accrued on notes payable, increase in derivative liabilities due to
the change in the fair value of derivative liabilities of $65,779, decrease in unearned interest of $5,151, increase in shares payable
to related parties of $601, and increase in salaries payable to related parties of $117,063.

 Net cash flows used in operating activities for
the year ended December 31, 2022 was $657,009, primarily attributable to net loss of $1,076,881, stock compensation expense of $900, discount
on note receivable of $4,719, and amortization of intangible assets of $49,500. The Company recorded a net change in operating assets
and liabilities of $364,756 attributable to net increase in accounts receivable of $17,661, decrease in accounts payable of $27,763, net
increase in accrued liabilities of $148,558, net increase in derivative liabilities of $267,257, increase in unearned interest of $5,151,
decrease in deferred revenues of $15,000, increase in shares payable to related parties of $14,624, and a net increase in salaries payable
to related parties of $10,410.

 __________________________

 Investing Activities

 Net cash used in investing activities for the
year ended December 31, 2023 was $0. Net cash used in investing activities for the year ended December 31, 2022 resulted due to cash advanced
for a promissory note receivable totaling $200,000.

 Financing Activities

 Net cash provided by financing activities for
the year ended December 31, 2023 was $113,872 primarily due to sale of our common stock of $51,872 net of costs incurred in capital raise,
and sale of Series B convertible preferred stock of $62,000. Cash provided by financing activities for the year ended December 31, 2022
was $843,524 primarily due to cash received from sale of common stock of $557,065 net of $11,141 cash paid for costs incurred in raising
capital, and cash received from sale of Series B convertible preferred stock of $297,600.

 As a result of the above activities, the Company
recorded a decrease in cash of $32,692 for the year ended December 31, 2023, and a decrease in cash of $13,485 for the same comparable
period ended December 31, 2022, respectively.

 The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As shown in the financial statements, the Company has suffered
continuing operating losses, has a working capital deficit of $2,067,461, used cash flows in operating activities of $146,564, and has
an accumulated deficit of $10,443,597 as of December 31, 2023. These factors, among others, raise substantial doubt about the Company's
ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

 Recently Issued Accounting Standards

 Other accounting standards that have been issued
or proposed by FASB and do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently
adopted would have a material effect on the accompanying financial statements.

 Off-Balance Sheet Arrangements

 We do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

 Item 7A.
 Quantitative And Qualitative Disclosures About Market Risk

 As a Smaller Reporting Company, we are not required
to furnish information under this Item 7A.

 Item 8.
 Financial Statements

 The financial statements and supplementary data
required by this item are included following the signature page of this Annual Report.

 Item 9.
 Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

 None.

 Item 9A.
 Controls and Procedures

 Disclosure Controls and Procedures

 We have established disclosure controls and procedures
that are designed to ensure that information required to be disclosed in reports filed or submitted under the Securities Exchange Act
of 1934, as amended (the " Exchange Act "), is recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission and, as such, is accumulated and communicated to our Chief Executive
Officer and Interim Chief Financial Officer, Clifford Emmons and Karen McNemar, respectively, who serve as our principal executive officer
and principal financial and accounting officer, respectively, as appropriate, to allow timely decisions regarding required disclosure.
Mr. Emmons and Ms. McNemar, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the
Exchange Act, as of December 31, 2023. Based on their evaluation, Mr. Emmons and Ms. McNemar concluded that, due to a material weakness
in our internal control over financial reporting as described below, our disclosure controls and procedures were not effective as of December
31, 2023. In light of the material weakness in internal control over financial reporting, we completed substantive procedures, including
validating the completeness and accuracy of the underlying data used for accounting prior to filing this Annual Report.

 These additional procedures have allowed us to
conclude that, notwithstanding the material weakness in our internal control over financial reporting, the consolidated financial statements
included in this report fairly present, in all material respects, our financial position, results of operations and cash flows for the
periods presented in conformity with accounting principles generally accepted in the United States of America.

 Management's Report on Internal Control
over Financial Reporting

 Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.

 Management conducted an evaluation of the effectiveness
of our internal control over financial reporting as of December 31, 2023 based upon Internal Control-Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (" COSO ").

 During its evaluation, management noted certain
matters involving internal control and its operation that we consider to be significant deficiencies or material weaknesses under standards
of the Public Company Accounting Oversight Board (" PCAOB "). A control deficiency exists when the design or operation
of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect
misstatements on a timely basis.

 A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the company's annual or interim financial statements will not be prevented or detected on a timely basis.

 We noted deficiencies involving lack of segregation
of duties, lack of governance/oversight, and lack of internal control documentation that we believe to be material weaknesses.

 Because of this material weaknesses, management
concluded that we did not maintain effective internal control over financial reporting as of December 31, 2023, based on criteria described
in Internal Control – Integrated Framework (2013) issued by COSO.

 Remediation of the Material Weakness

 We are evaluating the material weaknesses and
developing a plan of remediation to strengthen our overall internal control over financial reporting. The remediation plan will include
the creation and adoption of a formal policy manual specifically dealing with financial controls.

 Due to a material weakness as disclosed in the
2022 Annual Report on Form 10-K, we committed to the same remediation plan, as disclosed above; however, due to lack of resources, we
were unable to execute the contemplated remediation plan sans appointing an interim Chief Financial Officer. If we are unable to increase
our workforce, we may never be able to implement the remediation plan proposed above.

 We are committed to maintaining a strong internal
control environment and we believe that these remediation efforts will represent significant improvements in our controls. We have started
to implement these steps, as disclosed above; however, some of these steps will take time to be fully integrated and confirmed to be effective
and sustainable. Additional controls may also be required over time. Until the remediation steps set forth above are fully implemented
and tested, the material weakness described above will continue to exist.

 Changes in Internal Control over Financial
Reporting

 There has been no change in our internal control
over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during our most recent fiscal quarter ended December 31,
2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 Item 9B.
 Other Information

 During the quarter ended December 31, 2023, no
director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is
defined in Item 408(a) of Regulation S-K.

 Item 9C.
 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Not applicable to the
Company.

 Item 10.
 Directors, Executive Officers and Corporate Governance

 Current Management

 The following table sets forth information concerning
our directors and executive officers:

 Name

 Position

 Age

 Executive Officers:

 Chief Executive Officer, President, and Interim Chief Technical Officer

 Chief Operating Officer and Interim Chief Financial Officer

 Directors:

 Director

 Vidhyadhar Mitta

 Director

 Directors are elected to serve until the next
annual meeting of stockholders and until their successors are elected and qualified. Directors are elected by a plurality of the votes
cast at the annual meeting of stockholders and hold office until the expiration of the term for which he or she was elected and until
a successor has been elected and qualified.

 A majority of the authorized number of directors
constitutes a quorum of the Board of Directors for the transaction of business. The directors must be present at the meeting to constitute
a quorum. However, any action required or permitted to be taken by the Board of Directors may be taken without a meeting if all members
of the Board of Directors individually or collectively consent in writing to the action.

 Business Experience of Executive Officers
and Directors

 The principal occupation and business experience
during the past five years for our executive officers and directors is as follows:

 Clifford L. Emmons: Mr. Emmons has
served as our Chief Executive Officer, President, and director since June 4, 2018 and as our Interim Chief Technology Officer since June
2, 2022. From 1995 to 2017, Mr. Emmons worked for Medtronic, a global leader in medical technology, services, and solutions, where
he served in various capacities including several Vice President and Director positions. Mr. Emmons is also the founder of AHI, LLC, a
consultancy firm. Mr. Emmons received an Executive Certificate in Strategy & Innovation from MIT, a Master's of Science in Management
Engineering from the University of Bridgeport, a Bachelor of Science in Electrical Engineering from the University of New Haven, and a
Bachelor of Science in Mechanical Engineering from the University of Connecticut.

 Karen McNemar: Ms. McNemar has served
as our Chief Operating Officer since September 20, 2018 and as our Interim Chief Financial Officer since June 2, 2022. From 1998 until
August 2017, Ms. McNemar served in many capacities for Medtronic which included as a Senior Director of R&D Operations. Ms. McNemar
is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building strong
and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful process
and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions to increase
organizational productivity and performance. Ms. McNemar received her Bachelor of Science in Industrial Engineering and Operations
Research.

 Vidhyadhar Mitta: Mr. Mitta has served
as a director of the Company since the closing of the reverse acquisition on July 28, 2017. Mr. Mitta has also served as a director of
OXYS since its inception on August 4, 2016. Since 2000, he has been the founder and President of Synergic Solutions Inc., a software development
company that designs custom software for a variety of industries including radio-medicine and associate allied health fields. In his position
as President, Mr. Mitta has responsibility for all aspects of Synergic Solutions including technical program guidance, employee supervision,
business development, and profit and loss responsibility. Mr. Mitta received a BS in Information Science & Technology from BMS College
of Engineering in 1995.

 Legal Proceedings

 During the past ten years there have been no events
under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability
and integrity of any of our directors or executive officers, and none of these persons has been involved in any judicial or administrative
proceedings resulting from involvement in mail or wire fraud or fraud in connection with any business entity, any judicial or administrative
proceedings based on violations of federal or state securities, commodities, banking or insurance laws or regulations, or any disciplinary
sanctions or orders imposed by a stock, commodities or derivatives exchange or other self-regulatory organization.

 Family Relationships

 There are no family relationships between any
of our directors and executive officers.

 Director Independence

 We are not currently subject to listing requirements
of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the board of directors
be "independent" and, as a result, we are not at this time required to have our Board of Directors comprised of a majority
of "independent directors."

 We currently have not established any committees
of the Board of Directors. Our Board of Directors may designate from among its members an executive committee and one or more other committees
in the future. We do not have a nominating committee or a nominating committee charter. Further, we do not have a policy with regard to
the consideration of any director candidates recommended by security holders. To date, other than as described above, no security holders
have made any such recommendations. The entire Board of Directors performs all functions that would otherwise be performed by committees.
Given the present size of our board it is not practical for us to have committees. If we are able to grow our business and increase our
operations, we intend to expand the size of our board and allocate responsibilities accordingly.

 Delinquent
Section 16(a) Reports

 Under U.S. securities
laws, directors, certain officers and persons holding more than 10% of our common stock must report their initial ownership of our common
stock and any changes in their ownership to the SEC. The SEC has designated specific due dates for these reports and we must identify
in this Annual Report those people who did not file these reports when due. Based solely on our review of copies of the reports filed
with the SEC, we believe that all reporting requirements for fiscal year 2023 were complied with by each person who at any time during
the 2023 fiscal year was a director or an executive officer or held more than 10% of our common stock.

 Code of Ethics

 On March 9, 2018, the Board of Directors adopted
a Code of Ethics (the " Code "). The purpose of the Code of Ethics is to deter wrongdoing and to promote:

 honest and ethical conduct;

 full, fair, accurate, timely, and understandable disclosure in reports and documents that a registrant files with, or submits to, the SEC and in other public communications made by the Company;

 avoidance and ethical handling of actual or apparent conflicts of interest, including disclosure to an appropriate person of any material transaction or relationship that reasonably could be expected to give rise to such a conflict;

 confidentiality of corporate information;

 protection and proper use of corporate assets and opportunities;

 compliance with applicable governmental laws, rules, and regulations;

 prompt internal reporting of any violations of this Code to an appropriate person; and

 accountability for adherence to the Code.

 The Code of Ethics applies to all directors, officers,
and employees of the Company and its subsidiaries, including, but not limited to, the Company's principal executive officer, principal
financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Ethics is available
at www.oxyscorp.com and is included as an exhibit to this Annual Report. The Company will provide any person, without charge and upon
request through our website, a copy of the Code of Ethics.

 Item 11.

 Executive Compensation

 The following table sets forth information concerning
the annual compensation awarded to, earned by, or paid to the following named executive officers for all services rendered in all capacities
to our company and its subsidiaries for the years ended December 31, 2023 and 2022.

 Summary Compensation Table

 Name and principal position

 Year

 Salary
 ($)

 Stock Awards
 ($)

 Total
 ($)

 Clifford Emmons (1)

 2023

 (2)

 2,221
 (3)

 102,221

 2022

 (4)

 –

 Karen McNemar (5)

 2023

 (6)

 2,221
 (7)

 102,221

 2022

 (8)

 –

 ________________________

 (1)

 Mr. Emmons was appointed as our CEO, President, and interim CFO on June 4, 2018.

 (2)

 As of December 31, 2023, Mr. Emmons was owed $138,619 in accrued and unpaid consulting fees and $10,630 in reimbursable expenses.

 (3)

 As of December 31, 2023, Mr. Emmons earned 1,500,000 shares of common stock valued at $2,221.

 (4)

 As of December 31, 2022, Mr. Emmons was owed $139,575 in accrued and unpaid consulting fees and $2,849 in reimbursable expenses.

 (5)

 Ms. McNemar was appointed as our COO effective as of September 20, 2018.

 (6)

 As of December 31, 2023, Ms. McNemar was owed $121,092 in accrued and unpaid consulting fees and $1,600 in reimbursable expenses.

 (7)

 As of December 31, 2023, Mc. McNemar earned 1,500,000 shares of common stock valued at $2,221.

 (8)

 As of December 31, 2022, Ms. McNemar was owed $134,849 in accrued and unpaid consulting fees.

 Emmons Employment Contract

 On June 2, 2022, the
Board of Directors (with Mr. Emmons abstaining) approved the Employment Contract dated effective April 1, 2022 with Mr. Emmons (the " Emmons
Contract "). The term of the Emmons Contract is from the effective date until the Emmons Contract is terminated pursuant to its
terms. The services to be provided by Mr. Emmons pursuant to the Emmons Contract are those customary for the positions in which he is
serving.

 Pursuant to the Emmons
Contract, Mr. Emmons shall receive an annual salary of $100,000 which accrues unless converted into shares of Common Stock of the Company
at a conversion rate specified in the Emmons Contract. If the Company reaches $1,000,000 in cumulative sales over a 12-month period, the
annual salary will increase to $150,000, commencing the following month. If the Company reaches $5,000,000 in cumulative sales over a
12-month period, the annual salary will increase to $200,000 commencing the following month.

 As of the effective date,
the Company will award to Mr. Emmons an aggregate of 7,000,000 shares of the Company's Common Stock which will vest as follows (the
" Emmons Contract Shares "):

 1.

 1,500,000 shares on the first-year anniversary of the effective date;

 2.

 2,500,000 shares on the second-year anniversary of the effective date; and

 3.

 3,000,000 shares on the third-year anniversary of the effective date.

 The Emmons Contract Shares
are awarded under the 2022 Plan. Vesting of the Emmons Contract Shares is subject to acceleration of vesting upon the occurrence of certain
events such as a Change of Control (as defined in the Emmons Contract) or the listing of the Company's Common Stock on a senior
exchange.

 McNemar Employment Contract

 On June 2, 2022, the
Board of Directors of Company approved the Employment Contract dated effective April 1, 2022 with Ms. McNemar (the " McNemar Contract ").
The term of the McNemar Contract is from the effective date until the McNemar Contract is terminated pursuant to its terms. The services
to be provided by Ms. McNemar pursuant to the McNemar Contract are those customary for the positions in which she is serving.

 Pursuant to the McNemar
Contract, Ms. McNemar shall receive an annual salary of $100,000 which accrues unless converted into shares of Common Stock of the Company
at a conversion rate specified in the McNemar Contract. If the Company reaches $1,000,000 in cumulative sales over a 12-month period,
the annual salary will increase to $150,000, commencing the following month. If the Company reaches $5,000,000 in cumulative sales over
a 12-month period, the annual salary will increase to $200,000, commencing the following month.

 As of the effective date,
the Company will award to Ms. McNemar an aggregate of 7,000,000 shares of the Company's Common Stock which will vest as follows
(the " McNemar Contract Shares "):

 1.

 1,500,000 shares on the first-year anniversary of the effective date;

 2.

 2,500,000 shares on the second-year anniversary of the effective date; and

 3.

 3,000,000 shares on the third-year anniversary of the effective date.

 The McNemar Contract
Shares are awarded under the 2022 Plan. Vesting of the McNemar Contract Shares is subject to acceleration of vesting upon the occurrence
of certain events such as a Change of Control (as defined in the McNemar Contract) or the listing of the Company's Common Stock
on a senior exchange.

 Equity Awards

 The following table provides information on stock
and option awards held by the named executive officers as of December 31, 2023:

 Stock Awards

 Market Value of

 Number of Shares

 Shares of Units of

 or Units of Stock that

 Stock that Have Not

 Grant

 Have Not Vested

 Vested

 Name

 Date

 (#)

 ($)

 6/2/22

 5,500,000

 (1)

 3,575

 6/2/22

 5,500,000

 (1)

 3,575

 (1)

 1,500,000 shares on the first-year anniversary of the grant date; 2,500,000 shares on the second-year anniversary of the grant date; and 3,000,000 shares on the third-year anniversary of the grant date

 Compensation of Directors

 Besides Mr. Emmons' compensation (whose
compensation is disclosed above), no compensation was awarded to, earned by, or paid to any remaining directors for services rendered
in all capacities to our Company and its subsidiaries for the year ended December 31, 2023.

 Item 12.
 Security Ownership of Certain Beneficial Owners and Management

 The following table and footnotes thereto set
forth information regarding the number of shares of common stock beneficially owned by (i) each director and named executive officer of
our company, (ii) each person known by us to be the beneficial owner of 5% or more of its issued and outstanding shares of common stock,
and (iii) named executive officers, executive officers, and directors of the Company as a group as of May 10, 2024. In calculating any
percentage in the following table of common stock beneficially owned by one or more persons named therein, the following table assumes
560,015,293 shares of common stock outstanding. Unless otherwise further indicated in the following table, the footnotes thereto and/or
elsewhere in this report, the persons and entities named in the following table have sole voting and sole investment power with respect
to the shares set forth opposite the shareholder's name, subject to community property laws, where applicable. Unless otherwise
indicated in the following table and/or the footnotes thereto, the address of our named executive officers and directors in the following
tables is: 705 Cambridge Street, Cambridge, MA 02141.

 Name and Address of Beneficial Owner

 Amount and

Nature of

Beneficial

Ownership (1)

 Percent of Class (1)

 Named Executive Officers and Directors

 Clifford Emmons

 326,874,827

 (2)

 37.12%

 300,599,058

 (3)

 35.17%

 Vidhyadhar Mitta

 229,130,295

 (4)

 29.10%

 Executive Officers, Named Executive Officers, and Directors as a Group (3 Persons)

 856,604,180

 61.06%

 _____________________

 (1)

 Under Rule 13d-3 of the Exchange Act, a
 beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding,
 relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and
 (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be
 beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares).
 In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example,
 upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage
 ownership of any person, the amount of shares outstanding is deemed to include the number of shares beneficially owned by such
 person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person
 as shown in the above table does not necessarily reflect the person's actual ownership or voting power with respect to the
 number of shares of common stock actually outstanding on the May 10, 2024.

 (2)

 Includes 319,814,327 shares of Common Stock issuable upon the conversion of $218,753 in accrued and unpaid consulting fees. Also includes 780,000 shares issuable upon the conversion of shares of Series A Preferred Stock owned by Mr. Emmons.

 (3)

 Includes 294,190,058 shares of Common Stock issuable upon the conversion of $201,226 in accrued and unpaid consulting fees. Also includes 604,500 shares issuable upon the conversion of shares of Series A Preferred Stock owned by Ms. McNemar.

 (4)

 Includes 1,562,500 shares issuable upon the exercise of warrants. Also includes 224,630,952 shares issuable upon the conversion of a note issued to Mr. Mitta. Lastly, includes 1,200,000 shares issuable upon the conversion of shares of Series A Preferred Stock owned by Mr. Mitta.

 The following table sets forth information known
to us regarding the beneficial ownership of our Series A Supervoting Preferred Stock as of May 10, 2024.

 Title of Class

 Name and address of

 beneficial owner

 Amount and nature of

 beneficial ownership

 Percent of Class

 Series A Supervoting Preferred Stock

 Vidhyadhar Mitta

 12,000

 46.43%

 7,800

 30.18%

 6,045

 23.39%

 The following table sets forth information known
to us regarding the beneficial ownership of our Series B Convertible Preferred Stock as of May 10, 2024.

 Title of Class

 Name and address of

 beneficial owner (1)

 Amount and nature of

 beneficial ownership

 Percent of Class

 Series B Convertible Preferred Stock

 GHS Investments, LLC

 100%

 The following table sets forth information known
to us regarding the beneficial ownership of our Series C Convertible Preferred Stock as of May 10, 2024.

 Title of Class

 Name and address of

 beneficial owner (1)

 Amount and nature of

 beneficial ownership

 Percent of Class

 Series C Convertible Preferred Stock

 Cambridge MedSpace LLC

 100%

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Certain Relationships and Related Transactions

 For transactions with our executive officers,
please see the disclosure under " Item 11. Executive Compensation. " above.

 Cambridge MedSpace Note

 On January 22, 2019, we entered into a Securities
Purchase Agreement with Cambridge MedSpace, LLC, a Massachusetts limited liability company for the purchase of a 5% Secured Convertible
Note in the principal amount of $55,000. The note was convertible, in whole or in part, into shares of our Common Stock, at any time at
a rate of $0.65 per share with fractions rounded up to the nearest whole share, unless paid in cash at our election. The note bears interest
at a rate of 5% per annum and interest payments will be made on an annual basis. The original maturity date of the note was January 22,
2020. The note is governed by the SPA and is secured by all our assets (but is not a senior secured note) pursuant to the Security Agreement.
In addition to the issuance of the note, we issued Cambridge MedSpace warrants to purchase one share of our Common Stock for 50% of the
number of shares of Common Stock issuable upon conversion of the note. Each warrant was originally immediately exercisable at $0.75 per
share and expires on January 22, 2024. The lender is owned by shareholders of the Company, or their affiliates, including Clifford L.
Emmons, our Chief Executive Officer, Interim Chief Financial Officer, and director.

 On June 12, 2020, the Company entered into Amendment
No. 1 to the note with Cambridge MedSpace pursuant to which the note was amended to extend the maturity date to March 1, 2021.

 On April 6, 2022, the Company entered into Amendment
No. 2 to the note with Cambridge MedSpace pursuant to which the maturity date as extended to March 1, 2024.

 Debt Exchange Agreement

 On February 5, 2024 we
entered into the Debt Exchange Agreement with Cambridge MedSpace LLC, an entity of which the Company's CEO, Clifford L. Emmons shares
ownership. Under the agreement, we agreed to issue to the Lender 57 shares of Series C Preferred Stock in exchange for the forgiveness
of $68,825 of principal ($55,000) and accrued and unpaid interest.

 Mitta Note

 On August 2, 2019, we entered into a Securities
Purchase Agreement with Vidhyadhar Mitta, a director of the Company, for the purchase of a 12% Secured Convertible Note in the principal
amount of up to $125,000. The note was originally convertible, in whole or in part, into shares of our Common Stock, at any time at a
rate of $0.08 per share with fractions rounded up to the nearest whole share, unless paid in cash at our election. The note bears interest
at a rate of 12% per annum and interest payments were originally to be made on a quarterly basis. The note originally matured August 2,
2021. On August 2, 2019, the first closing of the note occurred pursuant to which we received $75,000. On September 6, 2019, the second
closing occurred pursuant to which the Company received $25,000. On October 16, 2019, the third closing occurred pursuant to which the
Company received $25,000.

 The note is governed by the SPA and is secured
by all the assets of the Company (but is not a senior secured note) pursuant to the Security Agreement. In addition to the issuance of
the note, we issued to the Mr. Mitta warrants to purchase one share our Common Stock for 50% of the number of shares of Common Stock issuable
upon conversion of the funds received. Each warrant was originally immediately exercisable at $0.12 per share and expires on August 2,
2024.

 On August 2, 2021, the Company entered into Amendment
No. 1 to the note with Vidhyadhar Mitta pursuant to which the note was amended to extend the maturity date to August 2, 2022.

 Effective August 2, 2022, the Company entered
into Amendment No. 1 to the note with Vidhyadhar Mitta pursuant to which the note was amended to extend the maturity date to August 2,
2024.

 Due to adjustments to the conversion price of
the note, the conversion price is currently $0.0008.

 Director Independence

 We are not currently subject to listing requirements
of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the board of directors
be "independent" and, as a result, we are not at this time required to have our Board of Directors comprised of a majority
of "independent directors." Although we have not adopted the independence standards any national securities exchange to determine
the independence of directors, the NYSE MKT LLC provides that a person will be considered an independent director if he or she is not
an officer of the company and is, in the view of our board of directors, free of any relationship that would interfere with the exercise
of independent judgment. Under this standard, our board of directors has determined that Mr. Mitta would meet this standard, and therefore,
would be considered to be independent.

 Item 14.
 Principal Accountant Fees and Services

 Fees Paid

 Audit Fees

 The aggregate fees billed for professional services
rendered by our principal accountants for the audit of our annual financial statements, review of financial statements included in the
quarterly reports and other fees that are normally provided by the accountant in connection with statutory and regulatory filings or engagements
for the year ended December 31, 2023 were $50,543 and $50,250 for the period ended December 31, 2022.

 Audit-Related Fees

 There were no fees billed for assurance and related
services by our principal accountants that are reasonably related to the performance of the audit or review of the financial statements,
other than those reported above, for the years ended December 31, 2023 and 2022.

 Tax Fees

 The aggregate fees billed for professional
services rendered by our principal accountants for tax compliance, tax advice and tax planning in the years ended December 31, 2023
were $0 and $3,500 in 2022.

 All Other Fees

 There were no other fees billed for products or
services provided by the principal accountants, other than those previously reported above, for the years ended December 31, 2023 and
2022.

 Audit Committee

 We do not have an Audit Committee; therefore,
the Board of Directors has considered whether the non-audit services provided by our auditors to us are compatible with maintaining the
independence of our auditors and concluded that the independence of our auditors is not compromised by the provision of such services.
Our Board of Directors pre-approves all auditing services and permitted non-audit services, including the fees and terms of those services,
to be performed for us by our independent auditor prior to engagement.

 Item 15.
 Exhibits, Financial Statement Schedules

 Financial Statements

 The following financial statements are filed with
this Annual Report:

 Report
of Independent Registered Public Accounting Firm for the year ended December 31, 2022

 Report of Independent Registered Public Accounting Firm for the year ended December 31, 2023

 Audited Consolidated Balance Sheets at December 31, 2023 and 2022

 Audited Consolidated Statements of Operations for the years ended December 31, 2023 and 2022

 Audited Consolidated Statements of Changes in Stockholders' Deficit for the years ended December 31, 2023 and 2022

 Audited Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

 Notes to Audited Consolidated Financial Statements

 Exhibits

 The following exhibits are included with this
Annual Report:

 Incorporated by Reference

 Filed

 Exhibit

 Filing

 Here-

 Number

 Exhibit Description

 Form

 File No.

 Exhibit

 Date

 with

 2.1 & 10.1

 Securities Exchange Agreement dated March 16, 2017, by and among Gotham Capital Holdings, Inc., OXYS Corp. and the Shareholders of OXYS Corp.

 2.1

 8/3/2017

 2.2 & 10.2

 Agreement and Plan of Merger dated July 10, 2017

 2.1

 3.1

 Nevada Articles of Incorporation for IIOT-OXYS, Inc.

 3.1

 3.2

 Bylaws for IIOT-OXYS, Inc.

 3.2

 3.3

 Nevada Articles of Merger dated July 14, 2017

 3.3

 3.4

 New Jersey Certificate of Merger dated October 26, 2017

 3.4

 3.5

 Articles of Exchange

 2.1

 1/12/2018

 3.6

 Certificate of Amendment to Articles of Incorporation filed with the Nevada Secretary of State effective January 18, 2021

 3.1

 1/19/2021

 3.7

 Certificate of Designation for Series B Convertible Preferred Stock

 3.1

 11/24/2020

 3.8

 Certificate of Designation filed with the Nevada Secretary of State on July 2, 2020

 3.1

 11/13/2020

 3.9

 Certificate of Designation filed with the Nevada Secretary of State on November 9, 2020

 3.2

 11/13/2020

 3.10

 Certificate of Designation filed with the Nevada Secretary of State on January 18, 2024

 3.1

 1/24/2024

 3.11

 Amendment No. 1 to the Certificate of Designation filed with the Nevada Secretary of State on February 12, 2024

 3.1

 2/16/2024

 4.1 & 10.3*

 2017 Stock Incentive Plan

 4.1

 12/19/2017

 4.2 & 10.4*

 2019 Stock Incentive Plan

 4.1

 10.5

 Form of 12% Senior Secured Convertible Note

 99.1

 2/13/2018

 10.6

 Amendment No. 1 to the 12% Senior Secured Convertible Promissory Note Issued to Sergey Gogin on January 22, 2018

 99.3

 10.7

 Amendment dated January 28, 2021 to Senior Secured Convertible Promissory Note with Sergey Gogin

 10.1

 5/17/2021

 10.8

 Amendment dated December 14, 2021 to Senior Secured Convertible Promissory Note with Sergey Gogin

 10.10

 4/14/2022

 10.9

 Amendment dated March 14, 2022 to Senior Secured Convertible Promissory Note with Sergey Gogin

 10.1

 5/16/2022

 10.10

 Amendment No. 5 to 12% Senior Secured Convertible Promissory Note dated effective March 1, 2023 with Sergey Gogin

 10.1

 11/13/23

 10.11

 Form of Securities Purchase Agreement

 99.2

 2/13/2018

 10.12

 Form of Security and Pledge Agreement

 99.3

 2/13/2018

 10.13

 Form of Warrant

 99.4

 2/13/2018

 10.14

 Amendment No. 1 to the Warrant Agreement Issued to Sergey Gogin on January 22, 2018

 99.4

 10.15

 Form of 12% Senior Secured Convertible Note

 99.5

 10.16

 Amendment No. 1 to Senior Secured Convertible Promissory Note with Catalytic Capital LLC

 10.2

 11/16/2020

 10.17

 Amendment dated January 28, 2021 to Senior Secured Convertible Promissory Note with Catalytic Capital, LLC

 10.2

 5/17/2021

 10.18

 Amendment No. 1 to Senior Secured Convertible Promissory Note with YVSGRAMORAH LLC

 10.3

 11/16/2020

 10.19

 Amendment dated January 28, 2021 to Senior Secured Convertible Promissory Note with YVSGRAMORAH LLC

 10.3

 5/17/2021

 10.20

 Amendment dated December 14, 2021 to Senior Secured Convertible Promissory Note with YVSGRAMORAH LLC

 10.20

 4/14/2022

 10.21

 Amendment dated March 14, 2022 to Senior Secured Convertible Promissory Note with YVSGRAMORAH LLC

 10.2

 5/16/2022

 10.22

 Amendment No. 5 to 12% Senior Secured Convertible Promissory Note dated effective March 1, 2023 with YVSGRAMORAH LLC

 10.2

 11/13/2023

 10.23

 Form of Securities Purchase Agreement

 99.6

 10.24

 Form of Security and Pledge Agreement

 99.7

 10.25

 Form of Warrant

 99.8

 10.26

 Securities Purchase Agreement with Cambridge MedSpace, LLC dated January 22, 2019

 99.1

 1/23/2019

 10.27

 5% Convertible Secured Note with Cambridge MedSpace, LLC dated January 22, 2019

 99.2

 1/23/2019

 10.28

 Security Agreement with Cambridge MedSpace, LLC dated January 22, 2019

 99.3

 1/23/2019

 10.29

 Warrant Agreement with Cambridge MedSpace, LLC dated January 22, 2019

 99.4

 1/23/2019

 10.30

 Securities Purchase Agreement with Vidhyadhar Mitta dated August 2, 2019

 99.1

 8/8/2019

 10.31

 12% Convertible Secured Note with Vidhyadhar Mitta dated August 2, 2019

 99.2

 8/8/2019

 10.32

 Amendment No. 1 to the 12% Secured Convertible Promissory Note dated effective August 2, 2021 with Vidhyadhar Mitta

 10.1

 11/15/2021

 10.33

 Amendment No. 2 to the 12% Secured Convertible Promissory Note dated effective August 2, 2022 with Vidhyadhar Mitta

 10.35

 4/13/2023

 10.34

 Amendment No. 2 to the 12% Secured Convertible Promissory Note dated effective August 2, 2022 with Vidhyadhar Mitta

 10.1

 5/22/2023

 10.35

 Security Agreement with Vidhyadhar Mitta dated August 2, 2019

 99.3

 8/8/2019

 10.36

 Warrant Agreement with Vidhyadhar Mitta dated August 2, 2019

 99.4

 8/8/2019

 10.37

 Warrant Agreement with Vidhyadhar Mitta dated September 6, 2019

 10.31

 6/23/2020

 10.38

 Warrant Agreement with Vidhyadhar Mitta dated October 16, 2019

 10.32

 6/23/2020

 10.39

 Equity Financing Agreement dated November 1, 2021 with GHS Investments, LLC

 S-1

 333-261484

 10.35

 12/3/2021

 10.40

 Registration Rights Agreement dated November 1, 2021 with GHS Investments, LLC

 S-1

 333-261484

 10.36

 12/3/2021

 10.41

 $75,000 Convertible Promissory Note dated July 29, 2020 issued to GHS Investments LLC

 99.4

 8/3/2020

 10.42

 Extension No. 1 to Convertible Promissory Note dated April 29, 2021 ($75,000) with GHS Investments LLC

 10.2

 8/13/2021

 10.43

 Amendment No. 2 dated November 4, 2021 to $75,000 Convertible Promissory Note issued to GHS Investments LLC

 S-1

 333-261484

 10.42

 12/3/2021

 10.44

 Amendment No. 3 dated April 29, 2022 to $75,000 Convertible Promissory Note issued to GHS Investments LLC

 S-1

 333-266351

 10.48

 7/27/2022

 10.45

 Extension No. 4 to the Convertible Promissory Note issued July 29, 2020 with GHS Investments LLC

 10.1

 8/18/2023

 10.46

 Collaboration Agreement effective March 18, 2020 with Aingura IIoT, S.L.

 10.1

 8/19/2020

 10.47

 Finder's Fee Agreement dated August 17, 2023 with J.H. Darbie & Co., Inc.

 10.3

 11/13/2023

 10.48*

 Debt Forgiveness Agreement with Clifford L. Emmons effective as of December 31, 2019

 10.3

 9/14/2020

 10.49*

 Debt Forgiveness Agreement with Karen McNemar effective as of December 31, 2019

 10.4

 9/14/2020

 10.50

 Securities Purchase Agreement dated November 16, 2020 with GHS Investments, LLC

 S-1

 333-252887

 10.52

 2/9/2021

 10.51

 Securities Purchase Agreement dated August 24, 2023 with GHS Investments, LLC

 10.4

 11/13/23

 10.52*

 Exchange Agreement Dated November 9, 2020 with Clifford L. Emmons

 S-1

 333-252887

 10.55

 2/9/2021

 10.53*

 Exchange Agreement Dated November 9, 2020 with Vidhyadhar Mitta

 S-1

 333-252887

 10.56

 2/9/2021

 10.54*

 Exchange Agreement Dated November 9, 2020 with Karen McNemar

 S-1

 333-252887

 10.57

 2/9/2021

 10.55

 Common Stock Purchase Agreement dated February 24, 2021 with GHS Investments, LLC

 10.4

 5/17/2021

 10.56*

 Employment Contract dated Effective April 1, 2022 with Clifford L. Emmons

 S-1

 333-266351

 10.63

 7/27/2022

 10.57*

 Employment Contract dated Effective April 1, 2022 with Karen McNemar

 S-1

 333-266351

 10.64

 7/27/2022

 10.58

 Debt Exchange Agreement dated February 5, 2024 with Cambridge MedSpace LLC

 X

 14.1

 Code of Ethics

 14.1

 4/17/2018

 16.1

 Letter from Haynie & Company Dated December 1, 2023 Regarding Change in Certifying Accountant

 16.1

 12/1/23

 21.1

 List of Subsidiaries

 21.1

 4/17/2018

 31.1

 Rule 13a-14(a) Certification by Principal Executive Officer

 X

 31.2

 Rule 13a-14(a) Certification by Principal Financial and Accounting Officer

 X

 32.1

 Section 1350 Certification of Principal Executive Officer

 X

 32.2

 Section 1350 Certification of Principal Financial and Accounting Officer

 X

 101.INS

 X

 101.SCH

 X

 101.CAL

 X

 101.DEF

 X

 101.LAB

 X

 101.PRE

 X

 X

 _________________

 *Management contract or compensatory plan or arrangement.

 Item 16
 Form 10-K Summary

 None.

 SIGNATURE PAGE FOLLOWS

 SIGNATURES

 Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

 IIOT-OXYS, INC.

 Date: July 3, 2024

 By:

 /s/ Clifford L. Emmons

 Clifford L. Emmons, Chief Executive Officer

 (Principal Executive Officer)

 Date: July 3, 2024

 By:

 /s/ Karen McNemar

 Karen McNemar, Interim Chief Financial Officer

 (Principal Financial and Accounting Officer)

 Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and
in the capacities and on the date indicated.

 NAME

 TITLE

 DATE

 /s/ Clifford L. Emmons

 Director and Chief Executive Officer (Principal Executive Officer)

 July 3, 2024

 /s/ Karen McNemar

 Interim Chief Financial Officer (Principal Financial and Accounting Officer

 July 3, 2024

 /s/ Vidhyadhar Mitta

 Director

 July 3, 2024

 Vidhyadhar Mitta

 INDEX TO FINANCIAL STATEMENTS

 Page

 Report of Independent Registered Public Accounting Firm for the year ended December 31, 2023

 Report of Independent Registered Public Accounting Firm for the year ended December 31, 2022

 Audited Consolidated Balance Sheets at December 31, 2023 and 2022

 Audited Consolidated Statements of Operations for the years ended December 31, 2023 and 2022

 Audited Consolidated Statements of Changes in Stockholders' Deficit for the years ended December 31, 2023 and 2022

 Audited Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

 Notes to Audited Consolidated Financial Statements

 F- 1

 REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors and Stockholders of IIOT-OXYS,
Inc.

 Opinion on the Financial Statements

 We have audited the accompanying consolidated
balance sheet of IIOT-OXYS, Inc. ("the Company") as of December 31, 2023, and the related consolidated statements of operations,
stockholders' equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the financial
statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles
generally accepted in the United States of America.

 Going Concern

 The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the Company has incurred net losses since inception and has negative cash flows from operations. These factors, among others, raise substantial
doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described
in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 F- 2

 Critical Audit Matters

 The critical audit matters communicated below
are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.

 Complex Equity Transactions

 As discussed in Note 9, the Company
has outstanding Series B Convertible Preferred stock that is required to be analyzed pursuant to ASC 815, Derivatives and Hedging. Management
uses an option pricing model to evaluate the fair value of its derivative liabilities, which requires management to make assumptions related
to fair value measurements. Calculations and accounting for these features require management's
judgments related to initial and subsequent recognition of the debt and related features, use of a valuation model, and value of the inputs
used in the selected valuation model.

 How We Addressed the Matter

 Our audit procedures related to the
evaluation of the Company's accounting for these instruments included the following, among others:

 o
 We obtained an understanding of management's process and methodology.

 o
 We independently evaluated the inputs utilized by management in order to determine the relevance and reliability
of data used.

 o
 We evaluated the underlying contracts and agreements and recalculated the fair value of derivative liabilities
and related disclosures.

 Fruci
& Associates II, PLLC – PCAOB ID # 5525

 We have served as the Company's auditor since 2024.

 Spokane, Washington

 July
3, 2024

 F- 3

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

 To the Board of Directors and

Stockholders of IIOT-OXYS, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying consolidated
balance sheet of IIOT-OXYS, Inc. (the Company) as of December 31, 2022, and the related consolidated statements of operations, stockholders'
equity (deficit), and cash flows for the year ended December 31, 2022, and the related consolidated notes (collectively referred to as
the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated
financial position of the Company as of December 31, 2022, and the results of its consolidated operations and its cash flows for the year
ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 Consideration of the Company's Ability
to Continue as a Going Concern

 The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the consolidated financial
statements, the Company has incurred net losses since inception and has negative cash flows from operations. These factors raise substantial
doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described
in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty.

 Basis for Opinion

 These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

 /s/ Haynie & Company

 Haynie & Company

 Salt Lake City, Utah

 April 13, 2023

 PCAOB ID: 457

 We began serving as the Company's auditors
in 2018. We became the predecessor auditor in 2023.

 F- 4

 Consolidated Balance Sheets

 December 31, 2023

 December 31, 2022

 ASSETS

 Current Assets

 Cash and cash equivalents

 $

 $
 33,336

 Accounts receivable, net

 5,460

 28,941

 Prepaid expenses and other current assets

 2,306

 7,773

 Total Current Assets

 8,410

 70,050

 Note receivable, net of discount of $ 0 and $ 4,716 at December 31, 2023 and 2022, respectively

 –

 195,284

 Intangible assets, net

 199,085

 248,585

 Total Assets

 $
 207,495

 $
 513,919

 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 Current Liabilities

 Accounts payable

 $
 219,551

 $
 133,408

 Accrued liabilities

 534,138

 395,714

 Deferred revenue

 31,425

 31,425

 Unearned interest

 –

 5,151

 Notes payable - current

 435,000

 363,167

 Shares payable to related parties

 15,225

 14,624

 Salaries payable to related parties

 380,579

 263,516

 Derivative liabilities

 535,653

 469,873

 Total Current Liabilities

 2,151,571

 1,676,878

 Notes payable

 58,988

 104,300

 Due to stockholders

 1,000

 1,000

 Total Liabilities

 2,211,559

 1,782,178

 Commitments and Contingencies (Note 5)

 –

 –

 Series B Convertible Preferred Stock, 600 shares designated, $ 0.001 Par Value, $ 1,200 stated value; 516 shares and 454 shares issued and outstanding at December 31, 2023 and 2022, respectively. Liquidation preference $ 619,200 and $ 544,800 at December 31, 2023 and 2022, respectively

 619,200

 544,800

 Stockholders' Equity (Deficit)

 Preferred Stock, $ 0.001 par value, 10,000,000 Shares authorized

 –

 –

 Series A Preferred Stock, 25,845
 shares issued and outstanding at December 31, 2023 and 2022, respectively

 Common Stock $ 0.001 Par Value, 1,000,000,000 shares authorized; 470,015,293 shares and 352,174,583 shares issued and outstanding at December 31, 2023 and 2022, respectively

 470,016

 352,175

 Additional paid in capital

 7,350,291

 7,141,877

 Accumulated deficit

 ( 10,443,597
)

 ( 9,307,137
)

 Total Stockholders' Equity (Deficit)

 ( 2,623,264
)

 ( 1,813,059
)

 Total Liabilities and Stockholders' Equity

 $
 207,495

 $
 513,919

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 5

 Consolidated Statements of Operations

 For The Year Ended December 31,

 2023

 2022

 Revenues

 $
 114,666

 $
 88,904

 Cost of Sales

 76,645

 10,499

 Gross Profit

 38,021

 78,405

 Operating Expenses

 Amortization of intangible assets

 Bad Debt

 214,103

 –

 General and administrative

 467,817

 683,571

 Total Operating Expenses

 731,420

 733,071

 Other Income (Expense)

 Gain (Loss) on change in FMV of derivative liability

 ( 4,100
)

 190,462

 Gain (Loss) on derivative

 ( 185,973
)

 ( 200,519
)

 Interest income

 25,969

 17,634

 Interest expense

 ( 210,426
)

 ( 377,138
)

 Total Other Income (Expense)

 ( 374,530
)

 ( 369,561
)

 Net Loss Before Income Taxes

 ( 1,067,929
)

 ( 1,024,227
)

 Provision for Income Tax

 –

 –

 Net Loss

 ( 1,067,929
)

 ( 1,024,227
)

 Convertible Preferred Stock Dividend

 ( 68,531
)

 ( 52,654
)

 Net Loss Attributable to Common Stockholders

 $
)

 $
)

 Net Profit (Loss) Per Share Attributable to Common Stockholders - Basic and Diluted

 $
 ( 0.00
)

 $
 ( 0.00
)

 Weighted Average Shares Outstanding Attributable to Common Stockholders - Basic and Diluted

 406,685,267

 273,238,664

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 6

 Consolidated Statements of Stockholders' Equity
(Deficit)

 For the Years Ended December 31, 2023 and 2022

 Preferred Stock

 Common Stock

 Series A

 Series B

 Amount

 Shares

 Amount

 Additional Paid-In Capital

 Accumulated Deficit

 Total Stockholders' Equity (Deficit)

 Balance - December 31, 2021

 25,845

 –

 –

 –

 $

 220,254,395

 $
 220,255

 $
 7,008,098

 $
 ( 8,544,232
)

 $
 ( 1,315,853
)

 Common Stock Issued for Financing Commitments

 –

 –

 –

 120,570,188

 120,570

 436,495

 –

 557,065

 Sales commissions paid on capital raise

 –

 –

 –

 –

 –

 ( 11,141
)

 –

 ( 11,141
)

 Common Stock Issued for Services

 –

 –

 –

 –

 Common stock issued for conversion of convertible note payables

 –

 –

 –

 11,250,000

 11,250

 78,750

 –

 90,000

 Beneficial Conversion Feature Associated with Discounts

 –

 –

 –

 –

 –

 ( 371,125
)

 313,976

 ( 57,149
)

 Net Loss

 –

 –

 –

 –

 –

 –

 –

 –

)

)

 Balance - December 31, 2022

 25,845

 –

 –

 –

 352,174,583

 352,175

 7,141,877

 ( 9,307,137
)

 ( 1,813,059
)

 Common stock issued for financing commitments

 –

 –

 –

 31,603,364

 31,604

 22,592

 –

 54,196

 Sales commissions paid on capital raise

 –

 –

 –

 –

 –

 ( 2,324
)

 –

 ( 2,324
)

 Common stock issued for services

 –

 –

 –

 3,450,000

 3,450

 1,215

 –

 4,665

 Common stock issued for settlement of accrued interest on note payable

 –

 –

 –

 20,000,000

 20,000

 ( 2,000
)

 –

 18,000

 Common stock issued for conversion of convertible note payables

 –

 –

 –

 62,787,345

 62,787

 2,637

 –

 65,424

 Loss on extinguishment of notes payable

 –

 –

 –

 –

 –

 186,294

 –

 186,294

 Net loss

 –

 –

 –

 –

 –

 –

 –

 –

)

)

 Balance - December 31, 2023

 25,845

 –

 –

 –

 $

 470,015,292

 $
 470,016

 $
 7,350,291

 $
 ( 10,443,597
)

 $
 ( 2,623,264
)

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 7

 Consolidated Statements of Cash Flows

 For the Year Ended December 31,

 2023

 2022

 Cash Flows From Operating Activities

 Net loss

 $
)

 $
)

 Adjustments to reconcile net loss to net cash (used) by operating activities

 Stock compensation expense for services

 4,665

 Bad debts

 214,103

 –

 Discount on note receivable

 –

 4,716

 Amortization of debt discount on notes payable and preferred stock

 12,400

 –

 Amortization of intangible assets

 Loss on extinguishment of notes payable

 186,294

 –

 Changes in Operating Assets and Liabilities

 Decrease (increase) in accounts receivable

 4,663

 ( 17,661
)

 Decrease in prepaid expenses and other current assets

 5,467

 –

 Increase (decrease) in accounts payable

 86,145

 ( 27,763
)

 Increase in accrued liabilities

 248,368

 148,558

 Increase in derivative liability

 65,779

 267,257

 (Decrease) increase in unearned interest

 ( 5,151
)

 5,151

 (Decrease) in deferred revenue

 –

 ( 15,000
)

 Increase in shares payable to related parties

 14,624

 Increase (decrease) in salaries payable to
 related parties

 117,063

 ( 10,410
)

 Net Cash Used by Operating Activities

 ( 146,564
)

 ( 657,009
)

 Cash Flows from Investing Activities

 Cash paid for note receivable

 –

 ( 200,000
)

 Net Cash used in Investing Activities

 –

 ( 200,000
)

 Cash Flows from Financing Activities

 Cash received from sale of common stock, net

 51,872

 545,924

 Proceeds from sale of Series B Preferred Stock

 62,000

 297,600

 Net Cash Provided by Financing Activities

 113,872

 843,524

 Net (Decrease) in Cash and Cash Equivalents

 ( 32,692
)

 ( 13,485
)

 Cash and Cash Equivalents - Beginning of Period

 33,336

 46,821

 Cash and Cash Equivalents - End of Period

 $

 $
 33,336

 Supplement Disclosures of Cash Flow Information

 Interest paid

 $
 –

 $
 –

 Income taxes paid

 $
 –

 $
 –

 Supplemental Disclosures of Non-Cash Investing and Financing Activities

 Discount on notes payable

 $
 –

 $
 32,852

 Conversion of convertible notes payable and derivative liabilities

 $
 4,665

 $
 90,000

 Deferred financing cost on notes payable

 $
 75,700

 $
 –

 Discount on Series B Convertible Preferred Stock

 $
 –

 $
 297,600

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 8

 Notes to Consolidated Financial Statements

 December 31, 2023 and 2022

 NOTE 1 - NATURE OF OPERATIONS, BASIS OF PRESENTATION
AND GOING CONCERN

 Unless otherwise indicated, any reference to "the
Company", "we", "us", or "its" refers to IIOT-OXYS, Inc., a Nevada corporation, and as applicable
to its wholly-owned subsidiaries, OXYS Corporation, a Nevada corporation, and HereLab, Inc., a Delaware corporation.

 IIOT-OXYS, Inc., incorporated in Nevada on July
6, 2017, (the " Company ") was established for the purpose of designing, building, testing, and selling Edge Computing
Systems for the Industrial Internet. The Company is currently devoting substantially all its efforts in identifying, developing and marketing
engineered products, software and services for applications in the Industrial Internet which involves collecting and processing data collected
from a wide variety of industrial systems and machines.

 Basis of Presentation

 The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (" GAAP ")
and include the accounts of the Company. The financial statements and accompanying notes are the representations of the Company's
management, who is responsible for their integrity and objectivity. In the opinion of the Company's management, the financial statements
reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.

 Principles of Consolidation

 The consolidated financial statements for the
years ended December 31, 2023 and 2022, respectively, include the accounts of Company, and its wholly-owned subsidiaries OXYS Corporation
and HereLab, Inc. All significant intercompany balances and transactions have been eliminated.

 Reclassifications

 Certain amounts in the prior periods presented
have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously
reported net income.

 F- 9

 Use of Estimates

 The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued
liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there
are material differences between the estimates and the actual results, future results of operations will be affected.

 Going Concern

 The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has
suffered continuing operating losses and reported a net loss of $ 1,136,460 for the year ended December 31, 2023, used cash flows in operating
activities of $ 146,564 and has recorded an accumulated deficit of $ 10,443,597 as of December 31, 2023. These factors, among others, raise
 substantial doubt about the Company's ability to continue as a going concern. If the Company is unable to obtain adequate capital,
it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability
and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to
continue as a going concern.

 Management believes that the Company will be able
to achieve a satisfactory level of liquidity to meet the Company's obligations for the next 12 months by generating cash through
additional borrowings and/or sale of equity securities, as needed. However, there can be no assurance that the Company will be able to
generate sufficient liquidity to maintain its operations. The financial statements do not include any adjustments that might result from
the outcome of these uncertainties.

 NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES

 The following summary of significant accounting
policies of the Company is presented to assist in the understanding of the Company's financial statements. These accounting policies
conform to GAAP in all material respects and have been consistently applied in preparing the accompanying financial statements.

 Cash and Cash Equivalents

 The Company considers all highly liquid
instruments with a maturity of three months or less at the time of issuance to be cash equivalents. The Company reported a cash
balance of $ 644
and $ 33,336
as of December 31, 2023 and 2022, respectively.

 Customer Concentration

 For the year ended December 31, 2023, 100 %
of revenue was derived from sales to one customer. For the year ended December 31, 2022, 100 %
of the revenues were derived from sales to two customers.

 Accounts Receivable and Allowance for Doubtful
Accounts

 Trade accounts receivable are carried at
original invoice amount less an estimate made for doubtful accounts. The Company determines the allowance for doubtful accounts by
identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts
and follows the guidelines and processes of measuring both current and expected future credit losses. Trade accounts receivable are
written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income when
received. The Company has adopted and implemented Accounting Standards Codification ("ASC") Topic 326 Financial
Instruments – Credit Losses during 2023 which has no impact on the financial statements as of December 31, 2023. There was no
allowance for doubtful accounts as of December 31, 2023 and December 31, 2022, respectively.

 F- 10

 Long-Lived Assets

 The Company regularly reviews the carrying value
and estimated lives of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to the carrying
value or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability
to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets
to the Company's business objectives.

 Definite-lived intangible assets are amortized
on a straight-line basis over the estimated periods benefited and are reviewed when appropriate for possible impairment.

 Basic and Diluted Earnings (Loss) Per Common Share

 The Company computes earnings (loss) per share
in accordance with Financial Accounting Standards Board Accounting Standards Codification ("ASC"), ASC 260, " Earnings
per Share". ASC 260 requires presentation of both basic and diluted earnings per share ("EPS") on the face of the
income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average
number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding
during the period using the treasury stock method and convertible note and preferred stock using the if-converted method. In computing
diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise
of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

 Revenue Recognition

 The Company recognize revenues when the products
are delivered to the customer or services are performed in accordance with the contractual terms of the contract with its customer. The
Company recognizes revenue in accordance with ASC Topic No. 606, Revenue from Contracts with Customers ("ASC 606")
which was adopted on January 1, 2018.

 According to ASC 606, the Company recognizes revenue
based on the following criteria:

 Identification of a contract or contracts, with a customer.

 Identification of performance obligations in the contract.

 Determination of contract price.

 Allocation of transaction price to the performance obligation.

 Recognition of revenue when, or as, performance obligation is satisfied.

 Advance payments received from customers for products
or services that are to be delivered or performed in the future are recorded as deferred revenues.

 The Company has elected to treat shipping and
handling activities as cost of sales. Additionally, the Company has elected to record revenue net of sales and other similar taxes.

 F- 11

 Concentration of Credit Risk

 Financial instruments that potentially expose
the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company's
policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure.
Accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC), up to $250,000. At December 31, 2023 and
December 31, 2022, the Company had no amounts in excess of the FDIC insurance limit.

 Fair Value of Financial Instruments and
Fair Value Measurements

 ASC 820, " Fair Value Measurements and
Disclosures", requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used
to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of
input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure
fair value:

 Level 1 applies to assets or liabilities for which
there are quoted prices in active markets for identical assets or liabilities.

 Level 2 applies to assets or liabilities for which
there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities
in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less
active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated
by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially
the full term of the asset or liability.

 Level 3 applies to assets or liabilities for which
there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or
liabilities. The Company recorded derivative liabilities as Level 3 to measure the fair value of the change in derivative
liabilities.

 The Company's consolidated financial instruments
consist principally of cash, accounts receivable, prepaid expenses, note receivable, accounts payable, accrued liabilities, notes payable
and related parties payable. The Company believes that the recorded values of all the financial instruments approximate their current
fair values because of their nature and respective maturity dates or durations.

 Income Taxes

 The Company accounts for income taxes using the
asset and liability method in accordance with ASC 740, " Income Taxes". The asset and liability method provide that
deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial
reporting and tax basis of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities
are measured using the currently enacted tax rates and laws. The Company records a valuation allowance to reduce deferred tax assets to
the amount that is believed more likely than not to be realized.

 The Company follows the provisions of ASC 740-10,
" Accounting for Uncertain Income Tax Positions." When tax returns are filed, it is highly certain that some positions
taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position
taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of
a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination.

 F- 12

 Convertible Debt and Convertible Preferred
Stock

 When the Company issues convertible debt or convertible
preferred stock, it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether
the instrument should be classified as a liability under ASC 480, Distinguishing Liabilities from Equity, and second whether the
conversion feature should be accounted for separately from the host instrument. A conversion feature of a convertible debt instrument
or certain convertible preferred stock would be separated from the convertible instrument and classified as a derivative liability if
the conversion feature, were it a standalone instrument, meets the definition of an "embedded derivative" in ASC 815, Derivatives
and Hedging. Generally, characteristics that require derivative treatment include, among others, when the conversion feature is not
indexed to the Company's equity, as defined in ASC 815-40, or when it must be settled either in cash or by issuing stock that is
readily convertible to cash. When a conversion feature meets the definition of an embedded derivative, it would be separated from the
host instrument and classified as a derivative liability carried on the consolidated balance sheet at fair value, with any changes in
its fair value recognized currently in the consolidated statements of operations.

 Effective January 1, 2022, we early adopted
ASU 2020-06, " Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in
an Entity's Own Equity" using the modified retrospective method of adoption. ASU 2020-06 simplifies the accounting for
convertible instruments by removing certain separation models in Subtopic 470- 20, Debt—Debt with Conversion and Other
Options, for convertible instruments. Under ASU 2020-06, the embedded conversion features no longer are separated from the host
contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic
815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a
convertible debt instrument will be accounted for as a single liability measured at its amortized cost as long as no other features
require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt
instruments typically will be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. We now
account for our Convertible Notes as single liabilities measured at amortized cost. As a result, the adoption of the guidance had a
material impact on the consolidated financial statements and accompanying notes, resulting in adjustments of $371,125, $313,976 and
$57,149 to the opening balance of additional paid-in capital, retained earnings, and long-term debt, respectively, as of January 1,
2022. We have updated our debt note (Note 5) with additional and modified disclosures as required by the standard upon
adoption.

 Recent Accounting Pronouncements

 In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 720): Improvements to Income Tax Disclosures ("ASU 2023-09"),
which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional
information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and
modifies certain other income tax-related disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and
allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the
adoption of ASU 2023-09 on its consolidated financial statements.

 In
November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment
Disclosures ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily
through enhanced disclosures about significant segment expenses. The disclosures requirements included in ASU 2023-07 are required
for all public entities, including those with a single reportable segment. ASU 2023-07 is effective for annual periods beginning
after December 15, 2024, on a retrospective basis, and early adoption is permitted. The Company is currently evaluating the
potential impact of ASU 2023-07 on its consolidated financial statements.

 NOTE 3 - NOTE RECEIVABLE

 On April 4, 2022, the Company issued an unsecured
convertible promissory note with the principal sum of $ 200,000 ("Note") with a company incorporated under the laws of the
Province of British Columbia. The Note bears an original issuance discount of $ 7,500 and matures on April 4, 2024. The interest on the
Note accrues at the rate of 10% per annum from the date of the Note, and will continue to accrue on the outstanding principal until the
entire balance is paid or converted into shares of common stock equal to 3.23% of the fully diluted share capital of the borrower on the
conversion date. The terms of the Note require the borrower to prepay (i) within 30 days of April 4, 2022, the first twelve months of
interest totaling $20,000, and (ii) within six months of April 4, 2022, the interest for the second twelve months under the Note totaling
$20,000. The Company will have the right, at its option on the maturity date, to convert all the principal sum into the common stock equal
to 3.23% of the fully diluted share capital of the borrower as of the conversion date. On April 4, 2022, the Company advanced to the borrower
$ 192,500 cash and recorded an original issuance discount on note receivable of $7,500. On April 21, 2022, the Company received $ 20,000
as prepaid interest from the borrower for the first twelve months of the Note.

 F- 13

 The Company recorded interest income earned on
the Note of $ 20,000 and $ 14,849 for the years ended December 31, 2023 and 2022, respectively. The Company amortized the discount on note
receivable and recorded it as interest income of $ 3,750 and $ 2,784 for the years ended December 31, 2023 and 2022, respectively. The Company
recorded unearned interest of $ 0 and $ 5,151, and reported unamortized original debt discount of $ 966 and $ 4,716 at December 31, 2023 and
2022, respectively.

 The noteholder is in default of paying $20,000
in interest payments within the six months of April 4, 2022, and has not made any principal payments on the Note to the Company. The
Company has provided an allowance for bad debt for the total amount of $ 200,000 of the Note and $ 15,068 of interest receivable on the
Note as of December 31, 2023.

 NOTE 4 - INTANGIBLE ASSETS

 The Company's intangible assets comprise
of intellectual property revolving around their field tests, sensor integrations, and board designs. Intangible assets, net of amortization
at December 31, 2023 and 2022, amounted to $ 199,085 and $ 248,585, respectively.

 Schedule of intangible assets

 December 31, 2023

 December 31, 2022

 Intangible Assets

 $
 495,000

 $
 495,000

 Accumulated amortization

 ( 295,915
)

 ( 246,415
)

 Intangible Assets, net

 $
 199,085

 $
 248,585

 The Company determined that none of its intangible
assets were impaired at December 31, 2023 and 2022, respectively. Amortizable intangible assets are amortized using the straight-line
method over their estimated useful lives of ten years. Amortization expense of finite-lived intangibles was $ 49,500 and $ 49,500 for the
years ended December 31, 2023 and 2022, respectively.

 The following table summarizes the Company's
estimated future amortization expense of intangible assets with finite lives as of December 31, 2023:

 Schedule of future amortization

 Amortization
 expense

 2024

 $

 2025

 2026

 2027

 Thereafter

 1,085

 Total

 $
 199,085

 NOTE 5 - COMMITMENTS AND CONTINGENCIES

 In prior years, the Company entered into consulting
agreements with one director, three executive officers, and one engineer of the Company, which include commitments to issue shares of
the Company's common stock from the Company's 2017 Stock Incentive Plan and 2019 Stock Incentive Plans. All the consulting
agreements have been terminated and shares have been issued in conjunction with the related separation agreements. According to the terms
of the agreements, 3,547,788 shares were vested and issued per the Company's 2017 Stock Incentive Plan as of December 31, 2023 and
2022, respectively, and 3,530,000 shares 3,080,000 shares were vested and issued per the Company's 2019 Stock Incentive Plan as
of December 31, 2023 and 2022, respectively.

 In the event that the agreement is terminated
by either party pursuant to the terms of the agreement, all unvested shares which have been earned shall vest on a pro-rata basis as of
the effective date of the termination of the agreement and all unearned, unvested shares shall be terminated. The value of the shares
was assigned at fair market value on the effective date of the agreement and the pro-rata number of shares earned was calculated and amortized
at the end of each reporting period.

 F- 14

 On March 18, 2022, the Company adopted 2022 Stock
Incentive Plan and reserved for issuance 20,000,000 shares of common stock for incentivizing its management team. Pursuant to the terms
of the 2022 Plan, 3,100,000 shares and 0 shares of common stock were vested and issued as of December 31, 2023 and 2022, respectively.

 Employment Agreement - CEO

 On
June 2, 2022, the Board approved an Employment Agreement with the CEO dated effective April 1, 2022 whereby, the CEO will receive an
annual salary of $100,000 which accrues unless converted into shares of common stock of the Company at a stipulated conversion rate.
If the Company reaches $1,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $150,000 commencing
the following month. If the Company reaches $5,000,000 in cumulative sales over a 12-month period, the annual salary will increase to
$200,000 commencing the following month. The Company awarded the CEO an aggregate of 7,000,000
 shares of the Company's common stock under the 2022 Stock Incentive Plan, which
will vest (i) 1,500,000
 shares on April 1, 2023, (ii) 2,500,000
 shares on April 1, 2024, and (iii) 3,000,000
 shares on April 1, 2025. The shares are valued at the 90% of the fair value
of the average share price of the shares of 30 trading days at the end of each quarter. The Company
has recorded $ 199,053
 and $ 142,424
 in salaries payable to the CEO as of December 31, 2023 and 2022, respectively.

 Employment Agreement – COO/Interim CFO

 On June 2, 2022, the Board approved an
Employment Agreement with the COO/Interim CFO dated effective April 1, 2022, whereby, the officer will receive an annual salary of
$100,000 which accrues unless converted into shares of common stock of the Company at a stipulated conversion rate. If the Company
reaches $1,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $150,000 commencing the following
month. If the Company reaches $5,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $200,000
commencing the following month. The Company awarded the COO/Interim CFO an aggregate of 7,000,000
shares of the Company common stock under the 2022 Stock Incentive Plan, which will vest (i) 1,500,000
shares on April 1, 2023, (ii) 2,500,000
shares on April 1, 2024, and (iii) 3,000,000
shares on April 1, 2025. The shares are valued at the 90% of the fair value of
the average share price of the shares of 30 trading days at the end of each quarter. The Company recorded $ 181,526
and $ 121,092
in salaries payable to the COO/Interim CFO as of December 31, 2023 and 2022, respectively.

 F- 15

 NOTE 6 - CONVERTIBLE NOTES PAYABLE

 The following table summarizes the outstanding
balance of convertible notes payable, interest and conversion rates as of December 31, 2023 and December 31, 2022, respectively.

 Schedule of convertible notes payable

 December 31, 2023

 December 31, 2022

 A. Convertible note payable to an investor with interest at 12%
 per annum, convertible at any time into shares of common stock at the lowest VWAP of $0.001 per share on December 31, 2023. The balance
 of principal and accrued and unpaid interest is payable on maturity on March 1, 2024, unless automatically extended for one-year
 periods if no Event of Default is existing. The note is secured by substantially all the assets of the Company.

 $
 205,000

 $
 205,000

 B. Convertible note payable to an investor with interest at 5% per annum, convertible
 at any time into shares of common stock at $0.00084 per share. Interest is payable annually with the balance of principal and interest
 due on maturity on March 1, 2024. The note is secured by substantially all the assets of the Company.

 55,000

 55,000

 D. Convertible note payable to an investor with interest at 12% per annum, convertible
 at any time into shares of common stock at the lowest VWAP of $0.001 per share on December 31, 2023. The balance of principal and
 accrued and unpaid interest is payable on March 1, 2024, unless automatically extended for one-year periods if no Event of Default
 is existing. The note is secured by substantially all the assets of the Company.

 50,000

 50,000

 E. Convertible note payable to a related party with interest at 12% per annum,
 convertible at any time into shares of common stock at $0.00084 per share. Interest is payable quarterly with the balance of principal
 and interest due on maturity on August 2, 2024. The note is secured by substantially all the assets of the Company.

 125,000

 125,000

 F. Convertible note payable to an investor with interest at 10% per annum,
 convertible at any time into shares of common stock at $0.01 per share. Principal and interest due on maturity on April 29, 2023.

 –

 33,167

 G. Convertible note payable to an investor with interest
 at 10% per annum, convertible at any time into shares of common stock at $0.0009 per share. Note was issued as payment for future
 fees to be incurred under the related Equity Financing Agreement. Principal and interest due on maturity on April 29, 2025. the
 note is secured by substantially all the assets of the Company.

 58,988

 75,000

 493,988

 543,167

 Less deferred financing costs

 –

 ( 75,700
)

 Net balance

 493,988

 467,467

 Less current portion

 ( 435,000
)

 ( 363,167
)

 Long term portion

 $
 58,988

 $
 104,300

 F- 16

 A.

 January
 18, 2018 Convertible Note and Warrants ("Note A")

 On March 14, 2022, the noteholder of Note A agreed
to extend the maturity date of March 1, 2022 of the Senior Secured Convertible Promissory Note to March 1, 2023, in exchange for the reduction
of the conversion price to $0.008 per share, and all prior Events of Default (as defined in the Note A) including penalties were waived,
and all future Events of Default (as defined in the Note A) pertaining to the future payment of interest were waived through maturity.
On July 21, 2023, the noteholder of Note A agreed to extend the maturity date to March 1, 2024, and Note A convertible into shares of
common stock on December 31, 2023 at the lowest VWAP of $0.001 per share during the look back period, provided:

 Upon request of the noteholder of Note A, the Company shall issue twenty thousand dollars ($20,000) worth of common shares (the "1 st Incentive Shares) and the price per 1 st Incentive Share shall be the Volume-Weighted Average Price (VWAP) per common share of the Company (subject to adjustments) for the previous ten trading days.

 The Company shall use its best efforts to file a registration statement registering the resales of the 1 st Incentive Shares within 45 calendar days from the date hereof. The Company shall use is best efforts to have the registration statement declared "effective" within sixty (60) calendar days from its filing. The Company shall use its best efforts to have a registration statement registering the resales of the 1st Incentive Shares remain effective until such time that the noteholder of Note A no longer holds any such 1st Incentive Shares.

 Upon full conversion of the Note A and Note D, the Company shall issue to the holder of Note A fifty thousand dollars ($50,000) worth of common shares (the "2nd Incentive Shares") and the price per 2nd Incentive Share shall be the VWAP per common share of the Company (subject to adjustments) for the previous ten (10) Trading Days.

 The Company shall use its best efforts to file a registration statement registering the resales of the 2nd Incentive Shares within forty-five (45) calendar days from the date of issuance. The Company shall use is best efforts to have the registration statement declared "effective" within sixty (60) calendar days from its filing. The Company shall use its best efforts to have a registration statement registering the resales of the 2nd Incentive Shares remain effective until such time that the noteholder of Note A no longer holds any such 2nd Incentive Shares.

 All other terms and conditions of the convertible
promissory note remain the same. The noteholder of Note A waives all events of default pertaining to the Note A, known or unknown to the
noteholder, by the Company prior to the date hereof. The noteholder also waives all defaults of the transaction documents, known or unknown
to the noteholder of Note A by the Company prior to the date hereof.

 The Company recorded interest expense of $ 24,600
and $ 28,832 for the years ended December 31, 2023 and 2022, respectively. Accrued interest payable on Note A was $ 184,468 and $ 159,868
as of December 31, 2023 and 2022, respectively.

 The principal balance payable on Note A amounted
to $ 205,000 at December 31, 2023 and 2022, respectively.

 B.

 January 2019 Convertible Note and Warrants ("Note B")

 Effective March 1, 2021, the noteholder of Note
B agreed to extend the maturity date of the Senior Secured Convertible Promissory Note to March 1, 2024, and all prior Events of Default
(as defined in the Note B) including penalties were waived, and all other terms of the Note B remain the same.

 The Company recorded interest expense of
$ 2,750
and $ 2,750
for the years ended December 31, 2023 and 2022, respectively. This note and accrued interest is due to a related party. Accrued
interest payable on Note B totaled $ 13,592
and $ 10,842
as of December 31, 2023 and 2022, respectively. The Company recorded a loss on extinguishment of $ 149,766 due to the
change in the conversion price of this convertible note as of December 31, 2023.

 The principal balance payable on Note B amounted
to $ 55,000 at December 31, 2023 and 2022, respectively.

 F- 17

 D.

 March 2019 Convertible Note and Warrants ("Note D")

 On March 14, 2022, the noteholder of Note D agreed
to extend the maturity date of March 1, 2022 of the Senior Secured Convertible Promissory Note to March 1, 2023, in exchange for the reduction
of the conversion price to $0.008 per share, and all prior Events of Default (as defined in the Note D) including penalties were waived,
and all future Events of Default (as defined in the Note D) pertaining to the future payment of interest were waived through maturity.
On July 21, 2023, the noteholder of Note A agreed to extend the maturity of March 1, 2023 date to March 1, 2024 and Note D convertible
into shares of common stock at December 31, 2023 at the lowest VWAP of $0.001 per share during the look back period (see Note A above").

 The Company recorded interest expense of
$ 6,000
and $ 6,000
for the years ended December 31, 2023 and 2022, respectively. Accrued interest payable on Note D was $ 26,698
and $ 20,698
as of December 31, 2023 and 2022, respectively. The Company recorded a loss on extinguishment of $ 36,528 due to the change in the
conversion price of this convertible note as of December 31, 2023. The principal balance payable on Note D amounted to $ 50,000
at December 31, 2023 and 2022, respectively.

 E.

 August 2019 Convertible Note and Warrants ("Note E")

 On August 2, 2021, the noteholder of Note E agreed
to extend the maturity date of the Senior Secured Convertible Promissory Note to August 2, 2024. All other terms and conditions of the
Note E remain the same.

 The Company recorded interest expense of $ 15,000
and $ 15,000 on Note E for the years ended December 31, 2023 and 2022, respectively. Accrued interest payable on Note E was $ 63,690 and
$ 48,690 as of December 31, 2023 and 2022, respectively. This note is payable to a related party. The principal balance payable on Note
E amounted to $ 125,000 as of December 31, 2023 and 2022, respectively.

 F.

 August 29, 2019 Convertible Note and Warrants ("Note F")

 On April 29, 2022, the noteholder of Note F
agreed to extend the maturity date of the Secured Convertible Promissory Note to April
29, 2023. All other terms and conditions of the Note F remain the same. On March 23, 2023, the noteholder of Note F converted
the principal balance of its convertible promissory note of $ 25,814
and $ 5,787
of accrued interest into 17,837,838
shares of common stock of the Company valued at the fair value of $0.00185 per share. Per the terms of Note F, the conversion rate
is 100% of the lowest traded price for the 15 days prior to the conversion date, with the lowest traded price of $0.00185 on March
22, 2023. On April 27, 2023, the noteholder of Note F converted the remaining principal balance of $ 7,353
and accrued interest of $ 71
into 4,949,507
shares of common stock of the Company at the lowest traded price of $0.0015 on April 21, 2023.

 The Company recorded interest expense of $ 829
and $ 3,317 for the years ended December 31, 2023 and 2022, respectively. Accrued interest payable on Note F was $ 0 and $ 5,029 as of December
31, 2023 and 2022, respectively. The principal balance payable on Note F amounted to $ 0 and $ 33,167 as of December 31, 2023 and 2022,
respectively.

 G.

 July 2020 Equity Financing Arrangement ("Note G")

 On April 29, 2022, the noteholder of Note G agreed
to extend the maturity date of the Secured Convertible Promissory Note to April 29, 2023. On May 1, 2023, the noteholder of Note G agreed
to extend the maturity date of the Secured Convertible Promissory Note to April 29, 2025. All other terms and conditions of the Note G
remain the same.

 On October 1, 2023, the noteholder G
converted $ 18,000
of accrued interest into 20
million shares of common stock at the conversion price of $ 0.0009
per share. Per the terms of Note G, the conversion rate is 100% of the lowest traded price for the 15 days prior to the conversion
date, with the lowest traded price of $0.0009 on September 27, 2023. On November 14, 2023, the noteholder of Note G converted $ 3,137
of principal and $ 7,863
of accrued interest into 20
million shares of common stock as the lowest traded price of $ 0.00055
on November 6, 2023. On December 14, 2023, the noteholder of note G converted $ 12,875
of principal and $ 1,125
of accrued interest into 20
million shares of common stock at the conversion price of $ 0.0007
per share, with the lowest traded price of $0.0007 on November 28, 2023.

 The Company recorded interest expense of $ 11,148
and $ 7,500 on Note G for the years ended December 31, 2023 and 2022, respectively. Accrued interest payable on Note G was $ 0 and $ 17,240
as of December 31, 2023 and 2022, respectively. In addition, as of December 31, 2023, the Company recorded interest
expense of $ 75,700 as historical deferred financing costs relating to the noteholder G's equity line commitment to the Company.

 The principal balance payable of Note G amounted
to $ 58,988 and $ 75,000 at December 31, 2023 and 2022, respectively.

 F- 18

 NOTE 7 - EARNINGS (LOSS) PER SHARE

 The following table sets forth the computation
of basic and diluted net loss per share of common stock for the years ended December 31, 2023 and 2022:

 Schedule of earnings per share

 Year ended

 2023

 2022

 Net loss attributable to common stockholders (basic)

 $
)

 $
)

 Shares used to compute net loss per common share, basic and diluted

 406,685,267

 273,238,664

 Net loss per share attributable to common stockholders, basic and diluted

 $
 ( 0.00
)

 $
 ( 0.00
)

 Basic net loss per share is calculated by dividing
net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing
net loss by the weighted-average number of common shares and common share equivalents outstanding for the period. Common stock equivalents
are only included when their effect is dilutive. The Company's potentially dilutive securities which include stock options, convertible
debt, convertible preferred stock and common stock warrants have been excluded from the computation of diluted net loss per share as they
would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares
outstanding due to the Company's net loss position.

 The following outstanding common stock equivalents
have been excluded from diluted net loss per common share for the years ended December 31, 2023 and 2022, respectively, because their
inclusion would be anti-dilutive:

 Schedule of anti dilutive shares

 As of December 31,

 2023

 2022

 Warrants to purchase common stock

 Potentially issuable shares related to convertible notes payable

 837,994,510

 366,996,915

 Total anti-dilutive common stock equivalents

 840,862,907

 369,865,312

 NOTE 8 - RELATED PARTIES

 At December 31, 2023 and 2022, the amount due
to two stockholders was $ 1,000 relating to depositing funds for opening bank accounts for the Company. The Company leases its current
office facility from these stockholders on a month-to-month basis at a monthly rent of $250 starting January 1, 2020. Rent expense totaled
$ 3,000 for each of the years ended December 31, 2023 and 2022, respectively. The Company has recorded $ 250 as rent payable to the stockholder
in accounts payable as of December 31, 2023 and 2022, respectively.

 The Company executed a convertible promissory
note payable with an officer and director (see Note B) and indebted in the principal amount of $ 55,000 and accrued interest payable of
$ 13,592 and $ 10,842 as of December 31, 2023 and 2022, respectively.

 The Company executed three convertible promissory
notes payable with a director (see Note E) and indebted in the principal amount of $ 125,000 and accrued interest payable of $ 63,690 and
$ 48,690 as of December 31, 2023 and 2022, respectively.

 The Company awarded shares payable to officers
and a director valued at $ 4,441 and $ 13,941 for the years ended December 31, 2023 and 2022, respectively, pursuant to the terms of an
exchange agreement (Note 5). Shares payable to officers and a director were $ 15,225 and $ 14,624 at December 31, 2023 and 2022, respectively.
No convertible preferred stock was issued to related parties in 2023 and 2022, respectively.

 F- 19

 NOTE 9 - STOCKHOLDERS' EQUITY

 Common Stock

 The Company has an authorized capital
of 3,000,000,000 shares of $ 0.001
 par value common stock and 10,000,000
shares of $ 0.001 par value preferred
stock. The Company had 470,015,293
 shares and 352,174,583 shares of common
stock, and 25,845
 shares of preferred stock, issued and outstanding as of December 31, 2023 and 2022, respectively. The Company's authorized
common stock was increased to 3,000,000,000 shares of $0.001 par value on May 28, 2024.

 Common Stock

 Holders of shares of common stock are entitled
to one vote for each share on all matters to be voted on by the stockholders. Holders of common stock do not have cumulative voting rights.
Holders of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors
in its discretion from funds legally available, therefore. In the event of liquidation, dissolution, or winding up of the Company, the
holders of common stock are entitled to share pro rata in all assets remaining after payment in full of all liabilities. All of the outstanding
shares of common stock are fully paid and non-assessable. Holders of common stock have no preemptive rights to purchase the Company's
common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock.

 On February 24, 2021, the Company entered into
a Common Stock Purchase Agreement with an investor pursuant to which the investor agreed to purchase up to $5,000,000 of the Company's
registered common stock at $0.015 per share. Pursuant to the Agreement, purchases may be made by the Company during the Commitment Period
(as defined in the Agreement) through the submission of a purchase notice to the investor no sooner than ten business days after the preceding
closing. No purchase notice can be made in an amount less than $10,000 or greater than $500,000 or greater than two times the average
of the daily trading dollar volume for the Company's common stock during the ten business days preceding the purchase date. Each
purchase notice is limited to the investor beneficially owning no more than 4.99% of the total outstanding common stock of the Company
at any given time. There are certain conditions precedent to each purchase including, among others, an effective registration statement
in place and the VWAP of the closing price of the Company's common stock greater than $0.0175 for the Company's common stock during
the five business days prior to the closing. From January 1, 2023 to December 31, 2023, the investor purchased 31,603,364 shares of common
stock for a cash consideration of $ 54,196.

 The Company issued to consultants 3,450,000 shares
of common stock valued at $ 4,665 for services rendered pursuant to consulting agreements for the year ended December 31, 2023. The common
stock issued to consultants was valued at the fair market value of the common stock on the date of issuance.

 On March 23, 2023, the noteholder of Note F converted
the principal balance of $ 25,814 and accrued interest of $ 7,186 into 17,837,838 shares of common stock. The shares issued were valued
at the fair value of common stock on the date of issuance.

 On April 27, 2023, the noteholder of Note F converted
the principal balance of $ 7,353 and accrued interest of $ 71 into 4,949,507 shares of common stock. The shares issued were valued at the
fair value of common stock on the date of issuance.

 On October 17, 2023, the Company issued to
noteholder of Note G 20,000,000
shares of common stock in settlement of accrued interest due of $ 18,000
on the convertible promissory note. The Company reclassified $2,000 from additional paid in capital due to below par-value issuance of shares.

 On November 14, 2023, the noteholder of Note G
converted the principal balance of $ 3,132 and accrued interest of $ 7,862 totaling $ 11,000 into 20,000,000 shares of common stock. The
shares issued were valued at the fair value of common stock on the date of issuance. The Company reclassified $9,000 from additional paid in capital due
to below par-value issuance of shares.

 F- 20

 On December 14, 2023, the noteholder of Note G
converted the principal balance of $ 12,875 and accrued interest of $ 1,125 totaling $ 14,000 into 20,000,000 shares of common stock. The
shares issued were valued at the fair value of common stock on the date of issuance. The Company reclassified $6,000 from additional paid in capital due
to below par-value issuance of shares.

 The Company recorded a loss on extinguishment
on Note B and Note D of $ 186,294 as a result of changes in conversion prices of the convertible promissory notes. The offset of the loss
was recorded to additional paid in capital as of December 31, 2023.

 As a result of all common stock issuances, the
Company recorded 470,015,293 shares and 352,174,583 shares of common stock issued and outstanding at December 31, 2023 and 2022, respectively.

 Stock Incentive Plans

 On December 14, 2017 (the "Effective Date"),
the Board of Directors of the Company approved the 2017 Stock Inventive Plan (the "2017 Plan"). Awards may be made under the
2017 Plan for up to 4,500,000 shares of common stock of the Company. All of the Company's employees, officers and directors, as
well as consultants and advisors to the Company are eligible to be granted awards under the 2017 Plan. No awards can be granted under
the 2017 Plan after the expiration of 10 years from the Effective Date but awards previously granted may extend beyond that date. Awards
may consist of both incentive and non-statutory options, restricted stock units, stock appreciation rights, and restricted stock awards.

 On March 11, 2019 (the "Effective Date")
the Board of Directors of the Company approved the 2019 Stock Incentive Plan (the "2019 Plan"). Awards may be made under the
Plan for up to 5,000,000 shares of common stock of the Company. All of the Company's employees, officers and directors, as well
as consultants and advisors to the Company are eligible to be granted awards under the 2019 Plan. No awards can be granted under the Plan
after the expiration of 10 years from the Effective Date but awards previously granted may extend beyond that date. Awards may consist
of both incentive and non-statutory options, restricted stock units, stock appreciation rights, and restricted stock awards.

 On
March 18, 2022, the Board of Directors approved and adopted the 2022 Stock Incentive Plan (the "2022 Plan"). Awards may
be made under the 2022 Plan for up to 20,000,000
shares of common stock of the Company, subject to adjustment as to the number and kind of shares awarded. Only employees and
directors of the Company or an Affiliated company are eligible to receive Incentive Options under the 2022 Plan. The Company awarded 7,000,000
shares of the Company's common stock to an officer and 7,000,000
shares of common stock to a director of the Company (see Note 5), both vesting 1,500,000 shares vesting on the first anniversary on
the date of issuance, 2,500,000 shares vesting on the second anniversary of the date of issuance, and 3,000,000 shares on the third
anniversary of the date of issuance. In addition, on October 3, 2022, the Company awarded 300,000
shares of common stock to an advisor vesting 100,000 shares on the first anniversary date of issuance, 100,000 shares vesting on the
second anniversary, and the remaining 100,000 vesting the third anniversary of the date of issuance. The common shares vested
pursuant to the 2022 Plan amounted to 3,100,000
shares at December 31, 2023 and the 11,200,000
shares remain unvested as of that date.

 For the
years ended December 31, 2023 and 2022, under the 2022 Plan, the Company recorded stock compensation expense of $ 4,441 and $ 14,624 for
 3,000,000 shares and 2,568,493 shares payable to an officer, an advisor and a director. The shares earned
are valued at the 90% of the average market price of the shares of 30 trading days at the end of each quarter.

 Shares earned and issued related to the consulting
agreements are issued under the 2017 Plan and the 2019 Plan (Note 5). Vesting of the shares is subject to acceleration of vesting upon
the occurrence of certain events such as a Change of Control (as defined in the agreement) or the listing of the Company's common
stock on a senior exchange.

 F- 21

 A summary of the status of the Company's
non-vested shares at December 31, 2023 and 2022 and changes during the year then ended, is presented below:

 Schedule of summary of non-vested shares

 2022 Stock Incentive Plan

 Shares of
 Common Stock

 Weighted
 Average

 Exercise
 Price

 Balance at December 31, 2021

 –

 $
 –

 Awarded

 14,300,000

 0.006146

 Vested

 –

 –

 Forfeited

 –

 –

 Balance at December 31, 2022

 14,300,000

 0.006146

 Awarded

 –

 –

 Vested

 ( 3,100,000
)

 –

 Forfeited

 –

 –

 Balance at December 31, 2023 – (Unvested)

 11,200,000

 $
 0.006146

 Balance at December 31, 2023 – (Vested)

 3,100,000

 –

 Total Options outstanding – December 31, 2023

 14,300,000

 $
 0.006146

 Preferred Stock

 Series A Supervoting Convertible Preferred
Stock

 On July 2, 2020, the Board of Directors of the
Corporation had authorized issuance of 15,600 shares of preferred stock, $ 0.001 par value per share, designated as Series A Supervoting
Preferred Stock.

 Dividends: Initially, there will be no
dividends due or payable on the Series A Supervoting Preferred Stock. Any future terms with respect to dividends shall be determined by
the Board consistent with the Corporation's Articles of Incorporation.

 Liquidation and Redemption Rights: Upon
the occurrence of a Liquidation Event (as defined below), the holders of Series A Supervoting Preferred Stock are entitled to receive
net assets on a pro-rata basis. Each holder of Series A Supervoting Preferred Stock is entitled to receive ratably any dividends declared
by the Board, if any, out of funds legally available for the payment of dividends. Liquidation Event means (i) the liquidation, dissolution
or winding-up, whether voluntary or involuntary, of the corporation, (ii) the purchase or redemption by the corporation of the shares
of any class of stock or the merger or consolidation of the corporation with or into any other corporation or corporations, or (iii) the
sale, license or lease of all or substantially all, or any material part of, the Corporation's assets.

 Conversion: Each holder of Series A Supervoting
Preferred Stock may voluntarily convert its shares into shares of common stock of the Corporation at a rate of 1:100 (as may be adjusted
for any combinations or splits with respect to such shares).

 Rank: All shares of the Series A Supervoting
Preferred Stock shall rank senior to the Corporation's (A) common stock, par value $0.001 per share, and any other class or series
of capital stock of the Corporation hereafter created.

 F- 22

 Voting Rights:

 A.

 If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.

 B.

 Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

 [twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A and any newly designated Preferred stock issued and outstanding at the time of voting}]

 Divided by:

 [the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

 With respect to all
matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent,
the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together
with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable
law or the Articles of Incorporation or Bylaws.

 The Company had 25,845 shares of Series A Preferred
Stock issued and outstanding at December 31, 2023 and 2022, respectively.

 Series B Convertible Preferred Stock Equity
Financing

 On November 16, 2020, the Board of Directors of
the Corporation had authorized issuance of up to 600 shares of preferred stock, $ 0.001 par value per share, designated as Series B Convertible
Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $ 1,200, subject to increase
set forth in the Certificate of Designation.

 Dividends: Each share of Series B Convertible
Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 12% per annum, payable quarterly,
beginning on the Original Issuance Date and ending on the date that such share of Series B Convertible Preferred Share has been converted
or redeemed (the "Dividend End Date"). Dividends may be paid in cash or in shares of Series B Convertible Preferred Stock.
From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be entitled
to receive, and the Corporation shall pay, dividends on shares of Series B Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock
basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares
of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous
sentence.

 Voting Rights: The Series B Convertible
Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not
in excess of 4.99% conversion limitation). However, as long as any shares of Series B Convertible Preferred Stock are outstanding, the
Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series B Convertible
Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series b Convertible
Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption
or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series b Convertible
Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series
b Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects
any rights of the Holders, (d) increase the number of authorized shares of Series B Convertible Preferred Stock, or (e) enter into any
agreement with respect to any of the foregoing.

 F- 23

 Liquidation: Upon any liquidation, dissolution
or winding-up of the Corporation, whether voluntary or involuntary (a "Liquidation"), the Holders shall be entitled to receive
out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends
thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series
B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets
of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be
ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable
thereon were paid in full.

 Conversion: Each share of Series B Convertible
Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder
thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value of such share
of Series B Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series b Convertible Preferred Stock shall
be the amount equal to the lowest traded price for the Company's common stock for the fifteen (15) Trading Days immediately preceding
the date of such conversion. All such foregoing determinations will be appropriately adjusted for any stock dividend, stock split, stock
combination, reclassification or similar transaction that proportionately decreases or increases the common stock during such measuring
period. Following an event of default, the Conversion price shall equal the lower of: (a) the then applicable Conversion Price; or (b)
a price per share equaling 80% of the lowest traded price for the Company's common stock during the ten (10) trading days preceding
the relevant Conversion.

 Redemption: The Series B Convertible Preferred
Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.

 115% of the stated value if the redemption takes place within 90 days of issuance;

 120% of the stated value if the redemption takes place after 90 days and within 120 days of issuance

 125% of the stated value if the redemption takes place after 120 days and within 180 days of issuance; and

 each share of Preferred Stock is redeemed one year from the day of issuance

 November 19, 2020

 On November 19, 2020, pursuant to the terms of
a Securities Purchase Agreement dated November 16, 2020 (the "SPA"), the Company entered into a new preferred equity financing
agreement with GHS Investments, LLC ("GHS") in the amount of up to $600,000. The SPA provides for GHS's purchase, from
time to time, of up to 600 shares of the newly-designated Series B Convertible Preferred Stock. The initial closing under the SPA consisted
of 45 shares of Series B Convertible Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $ 45,000,
or $1,000 per share. At the Company's option, and subject to the terms of the SPA and the Certificate of Designation for the Series
B Convertible Preferred Stock (the "COD"), additional closings in the amount of 40 shares of Series B Convertible Preferred
Stock for a total purchase price of $40,000 may take place at a rate of up to once every 30 days. In connection with the initial closing
in the amount of 45 shares of Series B Convertible Preferred Stock, the Company issued an additional 25 shares of Series B Convertible
Preferred Stock to GHS as a commitment fee.

 No additional closings may take place after the
two-year anniversary of the SPA, or once the entire $600,000 amount has been funded. If the average daily dollar trading volume for the
Company's common stock for the 30 trading days preceding a particular additional closing is at least $50,000 per day, the Company
may, at its option, increase the amount of that additional closing to 75 shares of Series B Convertible Preferred Stock ($75,000).

 The Series B Convertible Preferred Stock is classified
as temporary equity, as it is convertible upon issuance at an amount equal to the lowest traded price for the Company's common stock
for the fifteen trading days immediately preceding the date of conversion.

 Based on the requirements of ASC 815, Derivatives
and Hedging, the conversion feature represents an embedded derivative that is required to be bifurcated and accounted for as a separate
derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each
conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting
period.

 F- 24

 On November 19, 2020, GHS purchased a total of
 70 shares of Series B Convertible Preferred Stock for gross proceeds of $ 45,000. The Company paid $ 900 in selling commissions to complete
this financing.

 On November 19, 2020 (the date of receipt of cash
proceeds of $45,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 103,267,
$ 58,267 as day one loss on the derivative, $ 39,000 as interest expense, and $ 39,000 as Series B Convertible Preferred Stock mezzanine
liability, and $ 45,000 as amortization.

 The Company recalculated the value of the derivative
liability associated with this convertible preferred stock recording a loss of $ 211 and a gain of $ 21,393 for the years ended December
31, 2023 and 2022, respectively, in connection with the change in fair market value of the derivative liability.

 The Company recorded $ 10,080 as preferred stock
dividend expense for each of the years ended December 31, 2023 and 2022, respectively. The Company recorded $ 31,400 and $ 21,320 as preferred
stock dividend payable as of December 31, 2023 and 2022, respectively. Derivative liability payable for this transaction totaled $ 72,667
and $ 72,456 at December 31, 2023 and 2022, and Series B Convertible Preferred Stock mezzanine liability was $ 84,000 at December 31, 2023
and 2022, respectively.

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0141, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0184, an expected dividend yield
of 0%, expected volatility ranging from 160.41% to 440.99%, risk-free interest rates ranging from 0.07% to 5.46%, and an expected term
ranging from 0.13 years to 1.50 years.

 December 16, 2020

 On December 16, 2020, pursuant to the terms of
the SPA, GHS purchased an additional 85 shares of Series B Convertible Preferred Stock for gross proceeds of $ 85,000. The Company paid
$ 1,700 in selling commissions to complete this financing.

 On December 16, 2020 (the date of receipt of cash
proceeds of $85,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 106,241,
$ 21,241 as day one loss on the derivative, $ 17,000 as interest expense, and $ 17,000 as Series B Convertible Preferred Stock mezzanine
liability, and $ 85,000 as amortization.

 The Company recalculated the value of the derivative
liability associated with this convertible preferred stock and recorded a loss of $ 256 and a gain of $ 31,043 for the years ended December
31, 2023 and 2022, respectively, in connection with the change in fair market value of the derivative liability. The Company recorded
preferred stock dividend expense of $ 12,240 for each of the years ended December 31, 2023 and 2022, respectively. The Company recorded
$ 37,223 and $ 24,983 as preferred stock dividend payable as of December 31, 2023 and 2022, respectively. Derivative liability payable for
this transaction totaled $ 88,238 and $ 87,982 at December 31, 2023 and 20222, and Series B Convertible Preferred Stock mezzanine liability
was $ 102,000 at December 31, 2023 and 2022, respectively.

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0141, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0184, an expected dividend yield
of 0%, expected volatility ranging from 160.41% to 437.59%, risk-free interest rates ranging from 0.07% to 5.46%, and an expected term
ranging from 0.21 years to 1.50 years.

 December 20, 2021

 On December 20, 2021, pursuant to the terms of
the SPA, GHS purchased an additional 51 shares of Series B Convertible Preferred Stock for gross proceeds of $ 51,000. The Company paid
$ 1,000 in selling commissions to complete this financing. For the year ended December 31, 2021, the Company inadvertently reported this
sale of 51 shares as Series A Preferred stock (See Series A Supervoting Preferred Stock). The accompanying financial statements reflect
the correct purchase of Series B Convertible Preferred Stock rather than Series A Convertible Preferred Stock. The overall effect of this
correction was not significant to the December 31, 2021 financial statements

 F- 25

 The Company recalculated the value of the derivative
liability associated with this convertible preferred stock recording a loss of $ 154 and $ 52,789 for the years ended December 31, 2023
and 2022, respectively, in connection with the change in fair market value of the derivative liability. In addition, the Company recorded
$ 9,200 in interest expense to record the fair value of derivative liability. The Company recorded $ 7,344 and $ 7,565 as preferred stock
dividend expense for the years ended December 31, 2023 and 2022, and $ 14,909 and $ 7,565 as preferred stock dividend payable as of December
31, 2023 and 2022, respectively. Derivative liability payable for this transaction totaled $ 52,943 and $ 52,789 at December 31, 2023 and
2022 and Series B Convertible Preferred Stock mezzanine liability was $ 61,200 at December 31, 2023 and 2022, respectively.

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.005 the closing
stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0070, an expected dividend yield of 0%,
expected volatility ranging from 174.58% to 221.64%, risk-free interest rates ranging from 0.91% to 5.46%, and an expected term of 1.50
years.

 February 7, 2022

 On February 7, 2022, pursuant to the terms of
the SPA, GHS purchased an additional 51 shares of Series B Convertible Preferred Stock for gross proceeds of $ 51,000. The Company paid
$ 1,000 in selling commissions to complete this financing.

 On February 7, 2022 (the date of receipt of cash
proceeds of $51,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 65,025,
$ 14,025 as day one loss on the derivative, $ 10,200 as interest expense, and $ 10,200 as Series B Convertible Preferred Stock mezzanine
liability, and $ 51,000 as amortization. The Company recalculated the value of the derivative liability associated with the convertible
note and recorded a loss of $ 154 and a gain of $ 12,234 for the years ended December 31, 2023 and 2022, respectively, in connection with
the change in fair market value of the derivative liability. In addition, the Company recorded $ 7,344 and $ 6,579 as preferred stock dividend
expense for the years ended December 31, 2023 and 2022, and preferred stock dividend payable to GHS on this derivative totaled $ 13,923
and $ 6,579 as of December 31, 2023 and 2022, respectively. Derivative liability payable for this transaction totaled $ 52,943 and $ 52,789
at December 31, 2022 and Series B Convertible Preferred Stock mezzanine liability was $ 61,200 at December 31, 2023 and 2022, respectively.

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0096, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0172, an expected dividend yield
of 0%, expected volatility ranging from 160.35% to 201.38%, risk-free interest rates ranging from 1.09% to 5.46%, and an expected term
of 1.35 to 1.5 years.

 March 24, 2022

 On March 24, 2022, pursuant to the terms of the
SPA, GHS purchased an additional 136 shares of Series B Convertible Preferred Stock for gross proceeds of $ 136,000. The Company paid $ 2,720
 in selling commissions to complete this financing.

 On March 24, 2022 (the date of receipt of cash
proceeds of $136,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 328,422,
$ 192,422 as day one loss on the derivative, $ 27,200 as interest expense, and $ 27,200 as Series B Convertible Preferred Stock mezzanine
liability, and $ 136,000 as amortization. The Company recalculated the value of the derivative liability associated with the convertible
note and recorded a loss of $ 410 and a gain of $ 187,650 for the years ended December 31, 2023 and 2022, in connection with the change
in fair market value of the derivative liability. In addition, the Company recorded preferred stock dividend expense of $ 19,584 and $ 15,131
for the years ended December 31, 2023 and 2022. Preferred stock dividend payable to GHS for this derivative totaled $ 34,715 and $ 15,131
at December 31, 2023 and 2022. Derivative liability payable for this transaction totaled $ 141,182 and $ 140,772 at December 31, 2023 and
2022, and Series B Convertible Preferred Stock mezzanine liability was $ 163,200 at December 31, 2023 and 2022, respectively.

 F- 26

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0096, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.00183, an expected dividend yield
of 0%, expected volatility ranging from 160.35% to 201.38%, risk-free interest rates ranging from 1.55% to 5.46%, and an expected term
of 1.48 to 1.5 years.

 November 17, 2022

 On November 17, 2022, pursuant to the terms of
the SPA, GHS purchased an additional 61 shares of Series B Convertible Preferred Stock for gross proceeds of $ 61,000. The Company paid
$ 1,220 in selling commissions to complete this financing.

 On November 17, 2022 (the date of receipt of cash
proceeds of $61,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 54,072,
$ 6,928 as day one gain on the derivative, $ 12,200 as interest expense, $ 12,200 as Series B Convertible Preferred Stock mezzanine liability,
and $ 61,000 as amortization. The Company recalculated the value of the derivative liability associated with the convertible note and recorded
a loss of $ 184 and $ 9,069 for the years ended December 31, 2023 and 2022, respectively, in connection with the change in fair market value
of the derivative liability. In addition, the Company recorded preferred stock dividend expense of $ 8,784 and $ 1,059 for the years ended
December 31, 2023 and 2022. Preferred stock dividend payable to GHS for this derivative totaled $ 9,843 and $ 1,059 at December 31, 2023
and 2022. Derivative liability payable for this transaction totaled $ 63,324 and $ 63,140 at December 31, 2023 and 2022, and Series B Convertible
Preferred Stock mezzanine liability was $ 73,200 at December 31, 2023 and 2022, respectively.

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0020, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0022, an expected dividend yield
of 0%, expected volatility ranging from 174.58% to 201.388%, risk-free interest rates ranging from 4.68% to 5.46%, and an expected term
of 1.5 years.

 August 24, 2023

 On August 24, 2023, pursuant to the terms of the
SPA, GHS purchased 62 shares of Series B Convertible Preferred Stock for gross proceeds of $ 62,000. The Company paid $ 1,240 in selling
commissions to complete this financing.

 On August 24, 2023 (the date of receipt of cash
proceeds of $62,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $ 61,679,
$ 321 as day one gain on the derivative, $ 12,400 as interest expense, and $ 12,400 as Series B Convertible Preferred Stock mezzanine liability,
and $ 62,000 as amortization.

 The Company recalculated the value of the derivative
liability associated with the convertible note at December 31, 2023 and recorded a loss of $ 2,732 for the year ended December 31, 2023,
in connection with the change in fair market value of the derivative liability. In addition, the Company recorded preferred stock dividend
expense of $ 3,155 for the year ended December 31, 2023. Preferred stock dividend payable to GHS for this derivative totaled $ 3,155 at
December 31, 2023. Derivative liability payable for this transaction totaled $ 64,411 at December 31, 2023 and Series B Convertible Preferred
Stock mezzanine liability was $ 74,400 at December 31, 2023.

 F- 27

the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0006 to $0.0014, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.00065 to $0.0015, an expected dividend
yield of 0%, expected volatility ranging from 189.98% to 201.38%, risk-free interest rates ranging from 4.79% to 5.46%, and an expected
term of 1.5 years.

 The following table represents the change in the
fair value of the derivative liabilities for the years ended December 31, 2023 and 2022, respectively.

 Level 1

 Level 2

 Level 3

 Balance at December 31, 2021

 $
 –

 $
 –

 $
 237,544

 Change in the fair value of derivative liability

 –

 –

 232,328

 Balance at December 31, 2022

 –

 –

 469,872

 Change in the fair value of derivative liability

 –

 –

 65,781

 Balance at December 31, 2023

 $
 –

 $
 –

 $
 535,653

 As a result of issuance of derivative instruments,
the Company recorded a derivative liability of $ 535,653 and $ 469,873 as of December 31, 2023 and 2022, and Series B Convertible Preferred
Stock liability of $ 619,200 and $ 544,800 as of December 31, 2023 and 2022, respectively.

 Warrants

 A summary of the status of the Company's
warrants as of December 31, 2023 and 2022 and changes during the years then ended, is presented below:

 Schedule of summary of warrant activity

 Shares
 Under
 Warrants

 Weighted
 Average
 Exercise Price

 Weighted
 Average
 Remaining
 Contractual Life

 Outstanding at December 31, 2021

 $
 0.00084

 2.4 Years

 Issued

 –

 –

 Expired/Forfeited

 –

 –

 Outstanding at December 31, 2022

 $
 0.00084

 1.4 Years

 Issued

 –

 –

 Exercised

 –

 –

 Expired/Forfeited

 –

 –

 Outstanding at December 31, 2023

 $
 0.00084

 0.4 Years

 F- 28

 NOTE 10 - INCOME TAXES

 Income tax expense for the year ended December
31, 2023 and 2022 is summarized as follows:

 Schedule of components of income tax expense (benefit)

 2023

 2022

 Deferred:

 Federal

 $
 ( 238,657
)

 $
 ( 226,145
)

 State

 ( 55,118
)

 ( 52,229
)

 Change in valuation allowance

 293,775

 278,374

 Income tax expense (benefit)

 $
 –

 $
 –

 The following is a reconciliation of the provision
for income taxes at the U.S. federal income tax rate to the income taxes reflected in the Statement of Operations:

 Schedule of effective income tax rate reconciliation

 2023

 2022

 Tax at statutory tax rate

 21.00 %

 21.00 %

 State taxes

 4.85 %

 4.85 %

 Other permanent items

 ( 0.02)%

 ( 0.24)%

 Valuation allowance

 - 25.83 %

 - 25.61 %

 Income tax expense

 –

 –

 The tax effects of temporary differences that
gave rise to significant portions of deferred tax assets and liabilities at December 31, 2023 and 2022 are as follows:

 Schedule of deferred tax assets and liabilities

 2023

 2022

 Deferred tax assets:

 Net operating loss carry forward

 $
 2,700,136

 $
 2,405,788

 Total gross deferred tax assets

 2,700,136

 2,405,788

 Less: valuation allowance

 ( 2,700,136
)

 ( 2,405,788
)

 Net deferred tax assets

 $
 –

 $
 –

 Deferred income taxes are provided for the tax
effects of transactions reported in the financial statements and consist of deferred taxes related primarily to differences between the
bases of certain assets and liabilities for financial and tax reporting. The deferred taxes represent the future tax return consequences
of those differences, which will either be deductible or taxable when the assets and liabilities are recovered or settled.

 F- 29

 At December 31, 2023 and 2022, the Company had
accumulated net operating losses of approximately $ 10,444,000 and $ 9,307,000, respectively, for U.S. federal and Massachusetts income tax
purposes available to offset future taxable incomes. The net operating losses generated in tax years prior to December 31, 2017, can carry
forward for twenty years, whereas the net operating losses generated after December 31, 2017 can carry forward indefinitely. Management
determined that it was unlikely that the Company's deferred tax assets would be realized and have provided for a full valuation
allowance associated with the net deferred tax assets.

 In the ordinary course of business, the Company's
income tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessment
by these taxing authorities. Accordingly, the Company believes that it is more likely than not that it will realize the benefits of tax
positions it has taken in its tax returns or for the amount of any tax benefit that exceeds the cumulative probability threshold in accordance
with FASB ASC 740. Differences between the estimated and actual amounts determined upon ultimate resolution, individually or in the aggregate,
are not expected to have a material adverse effect on the Company's financial position. The Company believes its tax positions are
all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for unrecognized tax benefits.
As of December 31, 2023, tax years 2022, 2021 and 2020 remain open for examination by the Internal Revenue Service and the Massachusetts
Division of Revenue. The Company has received no notice of audit from the Internal Revenue Service or the Massachusetts Division of Revenue for
any of the open tax years.

 NOTE 11 - SUBSEQUENT EVENTS

 Management has evaluated subsequent events through
the date of this Report, the date the financial statements were available to be issued, noting the following items that would impact the
accounting for events or transactions in the current period or require additional disclosure.

 On January 4, 2024, the noteholder of Convertible
Promissory Note G elected to convert $9,381 of the principal amount of the note and accrued and unpaid interest of $619 into 20,000,000
shares of common stock at the conversion price the lowest traded price of $0.0005 per share.

 On January 25, 2024, the noteholder of Convertible
Promissory Note G elected to convert $9,480 of the principal amount of the note and accrued and unpaid interest of $520 into 20,000,000
shares of common stock at the conversion price of the lowest traded price of $0.0005 per share.

 On February 5, 2024, the Company and the noteholder
of Convertible Promissory Note B entered into a Debt Exchange Agreement to convert $55,000 principal balance of Note B and $14,600 of
accrued and unpaid interest as of the maturity date of Note B on March 1, 2024. In exchange for the cancellation of all indebtedness of
the Company owed to the noteholder B as evidenced by the Convertible Note, and for no additional consideration, the Company agreed to
issue to the noteholder B, 57 shares of the Company's Series C convertible preferred stock at the stated value of $1,200 per share.

 On February 19, 2024, the noteholder of Convertible
Promissory Note G elected to convert $11,499 of the principal amount of the note and accrued and unpaid interest of $501 into 20,000,000
shares of common stock at the conversion price the lowest traded price of $0.0006 per share.

 On March 12, 2024, the noteholder of Convertible
Promissory Note G elected to convert $14,686 of the principal amount of the note and accrued and unpaid interest of $314 into 25,000,000
shares of common stock at the conversion price the lowest traded price of $0.0006 per share.

 On April 15, 2024, pursuant to the terms of the
SPA, GHS purchased 20 shares of Series B Convertible Preferred Stock for gross proceeds of $20,000. The Company paid $400 in selling commissions
to complete this financing and $2,000 in purchaser's legal fees.

 On May 28, 2024, the Company filed an amendment
to its Articles of Incorporation increasing its authorized common shares to 3,000,000,000.

 F- 30